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Abstract 
 
Access to novel opioid receptor binding ligands is important as chronic pain 
continues to be a pervasive problem in healthcare. The hasubanan (HB) alkaloids have 
been identified as potential candidates for selective opioid receptor binding. These 
alkaloids are a family of compounds, primarily isolated from the flowering plants of the 
sp Stephania, which have been used for centuries in traditional medicinal remedies. 
While morphine and HB alkaloids share several structural features, the natural occurring 
HB alkaloids have a configuration opposite to that of morphine. The unnatural antipodes 
of the HB alkaloids have a similar spatial orientation to morphine, making then 
increasingly attractive as potential analgesic therapeutics. Based on these observations we 
were inspired to develop a synthetic strategy that allows access to both the natural and 
unnatural enantiomers for several of the HB alkaloid family members.  
Chapter One provides a detailed background on pain and the involvement of the 
opioid receptors. Chapter Two covered the isolation and biosynthetic proposals of the HB 
alkaloids as well as a discussion of synthetic efforts that have been carried out and a 
structural analysis of the HB alkaloids. Chapter Three will cover our own synthetic 
efforts toward the synthesis of the HB alkaloid core.  
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CHAPTER 1                
INRODUCTION AND BACKGROUND 
 
Pain is defined as an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage.1 The prevalence of chronic pain in the United States is 
estimated to be 35.5 % or 105 million people; costs an estimated $100 billion USD per 
year in health-care expenditures and is the most common ailment for which patients seek 
medical attention.2,3 The experience of pain is highly subjective, with individuals 
developing pain thresholds through experiences of injury or pathology in early life. This 
inherit patient variability complicates clinical strategies for pain management with 50 % 
of individuals seeking treatment dissatisfied with their present treatment options.4 
Despite recent advancements in the use of analgesic adjuvants and the 
controversial selective cyclooxygenase 2 (COX-2) inhibitors, the mainstays of pain 
management continue to be non-steroidal anti-inflammatory drugs (NSAIDs), and opioid 
analgesics.5,6 Unfortunately, many of these can be ineffectual at managing pain and are 
further marred by adverse effects including the potential for abuse or dependence. 
Therefore, there is a major unmet challenge in the identification of compounds that can 
more effectively manage chronic pain, with fewer adverse side effects. We feel this 
challenge is best met through the synthesis of novel compounds derived from the 
hasubanan (HB) family of alkaloids.     
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 The HB alkaloids, primarily isolated from the vine Stephania japonica, have been 
used in traditional medicinal remedies for centuries.7,8 There has been significant interest 
in the HB alkaloids due to the close resemblance of the HB skeleton to that of morphinan 
alkaloids.9 Additionally, recent studies by Quinn and co-workers revealed an affinity of 
HB alkaloids for binding opioid receptors, which are common targets of several analgesic 
drug classes.10  
There have been numerous synthetic studies of the HB alkaloids, but none have 
established the analgesic potential of the HB alkaloids, and only a few of these synthetic 
routes are amenable to the necessary structural activity studies.11–14 The goal of this 
dissertation research is to develop a synthetic strategy that allows for the rapid synthesis 
of several HB alkaloids derivatives, which is required to complete a full biological 
evaluation of the HB alkaloids.  
This introduction (Chapter One) will provide background on the current approaches 
to pain management including by a description of analgesic drug classes and their 
respective mechanisms of action. Chapter Two, will provide an overview of the HB 
alkaloids and a discussion of the structural similarities between morphine and the HB 
alkaloids and the biological implications. Finally, Chapter Three will provide an in depth 
analysis and discussion on the synthetic work that was involved in making these HB 
derivatives.  
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1.1 Pain Management
1.1.1 Classification and etiology
 While several taxo
below (Figure 1.1); where 
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Figure 1.1. Pain classification by duration and etiology
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demarcation between acute and chronic pain is somewhat arbitrary, and typically ranges 
from three months to six months.16 Acute pain is highly receptive to treatment, as several 
classes of analgesics, including NSAIDs and weak opioids, are known to be clinically 
effective. 
The complexity of chronic pain has represented a major dilemma for clinicians, 
with one in three adult Americans seeking treatment for chronic pain annually.17 Chronic 
pain often has both adaptive (necessary for survival) and non-adaptive components. This 
multifactorial nature requires physicians to consider the origin of pain when developing 
treatment plans.18 Below is a brief description of the most common pain etiologies, 
nociceptive and neuropathic pain. 
1.1.1.b Nociceptive pain 
Nociceptive pain is frequently described as stabbing, pricking, burning, throbbing 
or cramping. It is instigated through the stimulation of specialized sensory neurons, called 
nociceptors, by noxious stimuli such as, extremes of temperature, or mechanical or 
chemical excitation. This type of pain serves as a warning to protect individuals from 
potential injury as illustrated by the automatic response of pulling away caused by briefly 
touching a hot surface. Nociceptive pain is often subcategorized as somatic, derived from 
skin and deep tissue, or as visceral, originating from internal organs. Due to high 
concentrations of nociceptors in somatic tissues, chronic nociceptive pain is typically 
localized, as in arthritis, which results from degenerative or inflammatory processes 
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within the joints.19 Nociceptive pain is often effectively managed with NSAIDs, or as in 
the case of post-operative pain, with a combination of NSAIDs and weak opioids.  
1.1.1.c Neuropathic pain 
 Neuropathic pain results from actual damage to nerve fibers themselves in the 
central or peripheral nervous system.20 This damage can lead to nerve dysfunction, 
causing numbness, weakness and/or loss of reflexes. Common descriptions 
accompanying neuropathic pain include “burning”, “shooting” or “shock-like” sensations. 
Central nervous system disorders of the brain or spinal cord, such as multiple sclerosis, 
and stroke frequently lead to neuropathic pain. Damage to peripheral nerves associated 
with amputation, radiculopathy, carpal tunnel syndrome also precipitate neuropathic 
pain.21 The most common cases of chronic neuropathic pain include diabetic neuropathy, 
post-herpetic neuralgia, fibromyalgia, and lower back pain due to disc herniation.22 There 
is a complex interplay between etiology, pathophysiology, and symptoms of neuropathic 
pain. Therefore, if one agent is not effective, physicians often use combination therapies 
that may mediate analgesia through different components of the involved pain pathways. 
1.1.2 Traditional chronic pain management approaches 
The treatment of chronic pain can be challenging because it is a complex 
condition influenced by genetic makeup as well as physiological and psychological 
factors. These factors are further complicated by the coexistence of both nociceptive and 
neuropathic pain. For instance, a cancer patient can experience pain from tumor 
encroachment, inflammatory pain due to tissue damage, and neuropathic pain resulting 
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management of neuropathic pain often requires a combination of drugs from different 
substance classes to produce adequate pain relief.  
Several clinicians adhere to the guidelines laid out in the World Heath 
Organization’s (WHO) Analgesic Ladder (Figure 1.3) for developing pain management 
plans.26 The WHO analgesic ladder provides a three-step sequential approach for 
analgesic administration based on pain severity. 
Figure 1.3. The WHO analgesic ladder. 
The ladder recommends initial treatment of pain with non-opioids, such as 
NSAIDs and acetaminophen. If pain persists, treatment with a weak opioid, in 
combination with a non-opioid analgesic is recommended followed by a strong opioid, 
until the patient is free of pain.27 At each stage of the treatment ladder, adjuvant 
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medications, such as antidepressants or anticonvulsants, may also be given to aid in 
alleviating patient pain and anxiety. Although recent advancements in the development of 
non-opioid analgesics have occurred, it is evident that opioids remain the mainstay of 
chronic pain management. 
1.1.3 Analgesics utilized in pain management 
1.1.3.a NSAIDs 
Compounds such as aspirin and ibuprofen, act by disrupting the synthesis of 
prostaglandins by inhibiting the cyclooxygenase enzymes COX-1 and COX-2. This 
inhibition of prostaglandin synthesis results in the analgesic, anti-pyretic and anti-
inflammatory properties of these drugs. Most NSAIDs are nonselective inhibitors of 
COX-1 and COX-2, but newly developed agents have much greater affinity for the COX-
2 isoform.28 Acetaminophen, which does not show anti-inflammatory affects, is also 
sometimes classified as an NSAID, but its mode of action for inhibiting prostaglandin 
synthesis has not been fully elucidated.29 The structures and mechanism of action of the 
most commonly utilized NSAIDs are shown in Table 1.1. The most commonly reported 
side effects of NSAIDs are those involving the GI tract. Additionally, chronic or acutely 
toxic acetaminophen exposure can lead to liver toxicity through hepatocellular 
necrosis.30,31  
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Table 1.1. Examples of NSAIDs and mechanism of action. 
Compound Mechanism of Action 
 
Non-selective inhibitor of COX-1 and COX-2 enzymes 
 
Non-selective inhibitor of COX-1 and COX-2 enzymes 
 
Inhibitor of prostaglandin synthesis; unknown mechanism 
 
Selective Inhibitor of COX-2 enzyme 
 
The adverse GI side effects of NSAIDs are attributed to the reduced prostaglandin 
levels in the gastrointestinal mucosa, which decreases mucus and bicarbonate secretions, 
thereby reducing their protective effects against the acidic gastric environment. In 
addition, NSAIDs can be directly toxic to the gastric mucosa, leading to ulceration, and 
potentially fatal bleeding in the most extreme cases.27 Selective COX-2 inhibitors cause 
less GI toxicity than non-selective COX-1 and COX-2 inhibitors, but several large studies 
have shown an increase in cardiovascular toxicity, including myocardial infarction and 
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stroke, associated with some selective COX-2 inhibitors.32 These selective inhibitors 
were withdrawn from the market between 2004 and 2005 because of this toxicity. 
Celecoxib is one of the main drugs in this class still employed.33 
1.1.3.b Analgesic adjuvants 
The term adjuvant analgesic describes any drug with a primary indication other 
than pain, but with analgesic properties in some conditions.34 Adjuvants are usually co-
administered with other analgesics such as NSAIDs and opioids, although some have 
been shown to have analgesic properties when administered alone.35 Tricyclic 
antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) are 
commonly used as adjuvant therapy. The explicit way in which antidepressants are 
effective in pain management remains unknown, but multiple mechanisms are likely to 
be involved. It is speculated that analgesia is mediated through inhibition of 
neurotransmitter reuptake in the synaptic cleft. These mechanisms are related to pain 
signaling in descending spinal pain pathways.36,37 Common side effects of TCAs are 
sedation, and anticholinergic consequences such as: dry mouth, constipation, postural 
hypotension and weight gain.38 While SSRI side effects are generally more mild than 
TCAs, there is the risk of weight gain with the long-term use of SSRIs, as well as sexual 
dysfunction.39  
Local anesthetics and some anticonvulsants are also used as analgesic adjuvants. 
These pharmacotherapies presumably produce a voltage-dependent blockade of calcium 
and/or sodium channels on damaged neurons, alleviating some pathologies associated 
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with neuropathic pain.24 Local anesthetics are often highly sedating and have a small 
therapeutic window before reaching toxicity, so their use as analgesic therapies is 
primarily restricted to hospital or clinical settings, or administered with controlled release 
transdermal patches. Side effects of anticonvulsants include drowsiness, dizziness and 
less commonly gastrointestinal symptoms and mild peripheral edema. All these effects 
require close monitoring and regularly require dosage adjustment. The structures and 
drug classes of commonly prescribed analgesic adjuvants are listed in Table 1.2. 
Table 1.2. Examples of analgesic adjuvants and drug classes. 
Compound Drug Class 
 
 
Tricyclic antidepressant: inhibit the reuptake of serotonin 
and norepinephrine at the synapse 
 
 
 
Selective serotonin reuptake inhibitor: inhibit the reuptake 
of serotonin at the synapse 
 
 
 
Local anesthetic: inhibitor of voltage-gated sodium channels 
 
 
Anticonvulsant: inhibitor of voltage-gated calcium channels 
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1.1.3.c Opioids1  
Opioids play a unique role in society, with a history tracing back to 3400 BC, 
Mesopotamia; where the Sumerians used the juice from unripe seed pods of the poppy, 
Papaver Sommniferum, to treat pain and other ailments. In 1805, Friedrich Sertürner 
isolated morphine (named from the Greek god of dreams) from opium, helping transform 
the landscape of modern medicine.40 Centuries later, opioids continue to be the 
cornerstone of treatment for moderate to severe pain. 
Opioids exert their analgesic properties through the binding of opioid receptors 
within the central nervous system. The binding of these receptors produces signals 
causing a hyperpolarization of neuronal cell membranes and the suppression of 
neurotransmitter release, resulting in analgesia. Numerous natural, semisynthetic, and 
synthetic opioids have been commercialized for oral, transdermal and intravenous 
administration (Table 1.3). The single entity formulations on the market include 
morphine (Avinza™, Kadian™, MS Contin™), oxycodone (OxyContin™), 
hydromorphone (Dilaudid™), oxymorphone (Opana™), fentanyl (Duragesic™, Actiq™, 
Fentora™), and methadone. Additionally several combination opioid/NSAID products, 
such as those containing hydrocodone and acetaminophen (Vicodin™, Lorset™) or 
ibuprofen (Vicoprofen™), tramadol and acetaminophen (Ultracet™), oxycodone and 
                                                 
1
 The term opioid refers to all compounds that bind to the opioid receptors. 
Conventionally, the term opiate can be used to describe those opioids that are alkaloids, 
derived from the opium poppy. Opioids include semisynthetic opiates, endogenous 
peptides, as well as synthetic opioids.  
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acetaminophen or aspirin (Percocet™ or Percodan™), and those containing codeine and 
acetaminophen are frequently used for the treatment of chronic pain.41 
Table 1.3. Examples opioids used in pain management. 
Natural 
 
Semi-synthetic 
 
Synthetic 
 
   
Opioids are far from benign medications, their long-term use is associated with 
significant side effects, including sleep apnea,42 constipation,43 hyperalgesia,44 tolerance, 
and addiction.45 Tolerance and addiction are particularly troublesome given the rate of 
overdose deaths in the United States has more than tripled since 1990,46 and the aberrant 
behaviors associated with addiction lead to significant criminal activity.  
Since the time of morphine’s isolation, scientists have attempted to develop opioids 
with a reduced propensity to cause the side effects associated with long-term use. Many 
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of these attempts have been based on flawed or incomplete hypotheses of tolerance 
development. As was the case of both diacetylmorphine (trade name Heroin) and 
sustained release oxycodone (trade name OxyContin), each initially was marketed as 
more effective and less habit forming than morphine.47 Now, both are come of the most 
highly sought after opioid drugs of abuse.  
Our understanding of the molecular mechanisms underlying opioid analgesia as 
well as tolerance and dependence has improved greatly with the study of the opioid 
receptors. The remainder of this chapter will focus on the insights into drug development 
gained through research of opioid receptor chemistry.  
1.2 Opioid Receptors 
1.2.1 Background and development of receptor pharmacophores 
In 1973, three independent teams identified opiate binding membrane receptors 
within the brain.48–50 Two years later scientists discovered endogenous peptides that bind 
to these receptors: enkephalins, β-endorphin, endomorphins, and dynorphins.51,52 By 
1976, scientists proposed the existence of three separate opioid receptor subtypes, µ 
(MOR), δ (DOR) and κ (KOR),53,54 which differ in their function and ligand specificity. 
The speed at which these discoveries were made was unprecedented compared to 
the discovery of other class of drugs. Early on, researchers observed the importance of 
subtle structural differences between agonists and antagonists (Figure 1.4 (A)).  
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Merely converting an N-methyl to an N-allyl substituent transformed the agonist 
(–)-morphine (1.1) to (–)-nalorphine (1.2), an opioid with partial antagonistic properties. 
The same modification of the agonist (–)- oxymorphone (1.3) leads to the full opioid 
receptor antagonist (–)-naloxone (1.4). By contrast, antagonists for most 
neurotransmitters and other drugs vary greatly in structure. 
A three-point pharmacophore of MOR binding was developed (Figure 1.4 (B)) 
based on specific spatial orientation of critical functional groups.55,56 These functional 
group requirements included a phenol, a hydrophobic region, and an amine. The size of 
the N-substituent dictated the compound’s potency and its agonist vs. antagonist 
properties. 
 
Figure 1.4. (a) Structural differences between MOR agonists and antagonists. (b) Generic 
3-point pharmacophore for OR receptors. 
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Scientists used this knowledge to prepare large numbers of radiolabelled opiates with 
widely varying potencies and efficacies, allowing them to rapidly probe receptor 
pharmacology and other fundamental aspects drug activity.57 
The advent of gene cloning and characterization further evolved our 
understanding of opioid receptors allowing the entire endogenous opioid system, 
including peptides and receptors to be characterized at the molecular level by the mid 
90s.58 Generation of chimeric receptors aided in identifying receptor regions important 
for binding, while site-directed mutagenesis studies were used to implicate individual 
residues involved in ligand binding.59 This knowledge produced a significantly more 
detailed pharmacophore in which specific binding interactions were proposed. One such 
proposal suggests that the phenol (Figure 1.4, (B)) interacts with a trans-membrane helix 
histidine residue, the amine interacts with an aspartate residue and the hydrophobic 
region fits into a pocket of hydrophobic residues (See Section 1.2.2 for a description of 
receptor structure).59  
Recently, after decades of studies, the crystal structures of MOR,60 DOR,61 and 
KOR62 with antagonist bound were disclosed, confirming several of the binding 
hypotheses and revealing new insights into receptor conformation, For example, the 
presence of extraneous molecules, such as water, within the opioid binding pocket. These 
structures will allow for the development of sophisticated computer-based binding 
models, which will hopefully lead to drug discovery. 
CHAPTER 1. INTRODUCTION AND BACKGROUND 
 
  
17
1.2.2 Receptor structure and function 
The opioid receptors, MOR, DOR, and KOR resemble rhodopsin and belong to 
the γ subfamily of class A G-protein-coupled receptors (GPCR).63 Each contains an 
extracellular N-terminus, seven counter-clockwise bundled trans-membrane helices, and 
an intracellular C-terminus.59,64 Overall MOR, DOR, and KOR show 70 % amino acid 
sequence identity. The most homology occurs within the seven trans-membrane helical 
core, which contains the opioid binding pocket.64 Three extracellular loops, including the 
N-terminal domain, differ strongly between receptors, and likely form a protein gate that 
selects agonists or antagonists entering the binding pocket, thereby contributing to µ, δ, 
and κ selectivity.65  
As with all GPCRs, opioid receptors convey extracellular signals within the cell 
through conformational modulation of the cytoplasmic domains that interact with the G 
protein.66 All three ORs interact with inhibitory G proteins of the Go/Gi type. Opioid 
induced analgesia occurs when ligand binding modifies the helical packing of the 
receptor, rearranging the positioning of trans-membrane domains. This helical movement 
modifies the receptor’s intracellular structure, disrupting the receptor-G protein 
interaction, catalyzing a nucleotide exchange on Gi and Go, which leads to inhibition of 
adenylyl cyclase, neuronal hyperpolarization via activation of K+ channels, and inhibition 
of neurotransmitter release via inhibition of Ca2+ channels.  
Following activation, receptors are decoupled from the G protein through rapid 
phosphorylation by GPCR kinases (GRKs) and subsequent binding by arrestin, resulting 
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in receptor desensitization.66 Arrestin additionally recruits clathrin and other components 
of the endocytic machinery, leading to endocytosis of the receptor, thus attenuating 
receptor signaling by removing ligand-receptor complexes from the cell surface. The 
receptors are re-sensitized by rapid recycling to the plasma membrane. There have been 
studies suggesting that ligands with the greatest addictive potential, promote interactions 
with Gi more strongly than they promote interactions with arrestins, leading researchers 
to believe that receptor trafficking plays a crucial role in the development of tolerance 
and dependence associated with the use of opioid drugs.67,68   
1.2.3 Receptor pharmacology 
The discrepancies in biological responses to the binding of opioids are due to 
differences in activity between the opioid receptors. The cloning of MOR, DOR and 
KOR receptors was an important step in probing these phenomena. Mice with genetic 
deletions of each of these receptors, as well as mice lacking two or three of the receptors 
have been generated, which has allowed researchers to identify unique pharmacological 
implications for each receptor.  
The most extensive investigations have involved MOR knockout mice. These 
studies have established that MOR is primarily responsible for analgesia elicited by 
morphine and a variety of other opioids. Further work showed that deletion of MOR 
abolishes tolerance and physical dependence to morphine.69  
Studies with KOR and DOR knockout mice have been also been fruitful. KOR 
was shown to mediate dysphoric activities and therefore was found to be useful in the 
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treatment of addiction by opposing the pleasure/reward response associated with MOR 
agonists.70 DOR was shown to be very distinct from MOR and KOR, with implications in 
the regulation of emotional responses and as well as anxiolytic and antidepressant activity, 
leading to potential interest in the field of psychiatric disorders.71 Selective DOR 
antagonists have also been shown to block the development of morphine tolerance and 
dependence72 giving rise to promising combination therapies for neuropathic pain without 
the adverse side effects associated with MOR.73 
1.2.4 Closing remarks 
The tools of molecular biology and computational modeling have greatly 
augmented insights into receptors and their ligands. Unfortunately, the pharmacologic 
alterations observed with the three different receptor subtypes have failed to address the 
two key problems to be resolved: 1) what is the nature of the addictive process and 2) is 
there a rational approach to the design of a less addicting opioid based on differential 
influences within the opioid receptors? Thus the current challenges in developing new 
opioid analgesics are remarkably similar to those almost 40 years ago, when opioid 
receptors were first identified. This conclusion is only bolstered by the pharmaceutical 
industry’s inability to develop treatments for chronic pain without the negative side 
effects associated with traditional MOR agonists. Drug development strategies, which 
have shown negligible success, continue to focus on solely on reformulation or drug 
combinations to attenuate the adverse side effects. If chronic pain is to be successfully 
treated, drug developers must look beyond improving efficacy and potency of MOR 
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agonists and consider additional properties that affect net receptor signaling, including 
receptor trafficking and signaling through non-canonical pathways such as arrestin.  
The identification of novel opioid receptor ligands with unique selectivity is 
needed in order to probe developing strategies in downstream signaling pathways. We 
feel strongly that this need is be met by investigating the binding interactions between the 
HB alkaloids and the opioid receptors and further studying their downstream effects. 
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CHAPTER 2                                  
THE HASUBANAN ALKALOIDS 
2.1 Introduction 
2.1.1 Isolation and structural elucidation 
 The HB alkaloids constitute, a large family of natural products, primarily isolated 
from the vine Stephania japonica. The greater than seventy HB family members which 
share a common aza[4.4.3]propellane core. The family is divided among four subclasses 
defined by the oxidation pattern of the C–ring (Figure 2.1).  Runanine (2.2) and 
delavayine (2.3) are the most closely related to the parent compound hasubanonine (2.1), 
with minor variations in A–ring substitutions, whereas cepharamine (2.4) and longanine 
(2.5) vary in oxidation at the C8 position. 
 
 Figure 2.1. Representative members of the hasubanan family of alkaloids. 
The premier family member hasubanonine (2.1), was isolated by Kondo and co-
workers in 1951.74 The structure of 2.1, however, was not elucidated until over a decade 
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after initial discosure.9 Due to the close structural resemblance to the morphinan alkaloids, 
the structure of hasubanonine was initially assigned as a morphinan analog, 2.6 (Figure 
2.2). In 1956, the structure was errantly amended, based on biogenetic considerations to 
2.7.75  
 
 
 
 
 
 Figure 2.2. Proposed structures of hasubanonine (2.1). 
The structure was not corrected until the mid-1960s, when Tomita and co-workers 
noted that the 1H NMR spectrum of hasubanonine lacked the characteristic C9–H 
resonance associated with the ethanamine bridge of the morphinan skeleton (2.8). This 
prompted the proposal of the hasubanan skeletal structure (2.9), which possesses a five- 
membered pyrrolidine ring as opposed to the six membered piperidine found in the 
morphinan alkaolids.76  
 
 
 
 
Figure 2.3. Numbered morphinan and hasubanan skeletons. 
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The authors confirmed their proposed structure by comparison of the physical and 
spectral properties of hasubanonine derivative 2.13 with known morphine derivative 2.14 
(Scheme 2.1). Preparation of compound 2.13 commenced with sodium borohydride 
reduction of hasubanonine, followed by acid catalyzed loss of methanol, to yield enone 
2.12. Further reduction of 2.12 with zinc amalgam in concentrated hydrochloric acid 
afforded the fully saturated amine 2.13.  
Scheme 2.1. Structure elucidation of hasubanonine (2.1). 
 
The NMR spectra of 2.13 confirmed the presence of the proposed five-membered 
pyrrolidine D–ring, with no signals attributable to an ethanamine bridge. The authors also 
noted that the physical properties of compounds 2.13 and 2.14 are identical with the 
exception of specific rotation, 2.13 is antipodal to 2.14, indicating an absolute 
configuration opposite to that of morphine. Thus the structure and absolute 
stereochemistry of (–)-hasubanonine (2.1) was unambiguously assigned. 
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2.1.2 Biosynthesis 
Due to the similarities in structure, early studies into the biosynthesis of the HB 
alkaloids were first directed by the knowledge established through the investigations into 
the biosynthesis of (–)-morphine (1.1).  
2.1.2.a Biosynthesis of morphine (1.1) 
The concept of phenolic oxidative radical coupling is a central theme in the 
biosynthesis of morphine (Scheme 2.2).75 The tyrosine derived 1-benzylisoquinoline 
intermediate, (R)-reticuline (2.15), undergoes oxidation to give 2.16, with resonance-
stabilized radicals at the ortho- position of the A–ring and para- position of the C–ring. 
Coupling of the intermediate radicals, followed by rearomatization leads to the dienone 
salutaridine (2.17). With the major framework established, subsequent cyclization, 
demethylation and reduction completes the biosynthesis of morphine (1.1). 
Scheme 2.2. Biosynthesis of morphine (1.1). 
 
2.1.2.b Biosynthetic studies of hasubanonine (2.1) 
To identify the radical cyclization precursor in the HB biosynthetic pathway, 
Battersby and co-workers, performed feeding experiments with several 13C-labelled 
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synthetic derivatives of 2.15.77,78 Based on these studies, dihydoxyisoquinoline, 2.18, was 
identified as an essential precursor for radical cyclization.  The authors also concluded 
that the timing of the N-methylation was not pivotal, as secondary amino or N-methylated 
isoquinolines were both successfully incorporated into the alkaloid. 
Little is known about the origins of the “enantiomeric” precursors 2.15 and 2.18. 
Both the morphinan and HB alkaloids are derived from tyrosine dimerization products. It 
has been suggested the same mechanistic pathway is shared by both alkaloid families for 
the generation of 2.15 and 2.18, but that the presence of different enzymes result in the 
formation of antipodal substrates. 
Scheme 2.3. Proposed biosynthesis of hasubanonine (2.1). 
 
There is also limited information about the ring contraction of morphinan dienone 
2.20, or its antipode, to form the hasubanan skeleton. Synthetic investigations by Kirby 
have shown that the alkaloid 2.21, bearing the morphinan framework, can be converted to 
the hasubanan framework through an aziridinium intermediate, by treatment with silver 
acetate (Scheme 2.4).79 
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Scheme 2.4. Conversion of the morphinan skeleton to the hasubanan skeleton. 
 
Presumably, the coordination of the allylic iodide to the silver metal generates a 
transient allylic carbocation. The tertiary amine undergoes an intramolecular SN2'-type 
substitution to give aziridinium ion 2.22, which is opened by an acetate anion at the less 
substituted position to provide 2.23 in 33 % yield. Kirby speculates that the formation of 
a similar aziridinium intermediate followed by enzymatic reduction is involved in HB 
alkaloid biosynthetic pathway.  
2.2 Synthetic Studies 
The challenging structures of the hasubanan alkaloids have garnered significant 
attention from the scientific community, with synthetic studies dating back to the 1960s. 
Racemic syntheses of hasubanonine (2.1),80 metaphanine,81,82 and cepharamine (2.4),83–85 
as well as numerous partial and formal syntheses of other hasubanan alkaloids86–97 have 
been reported. More recently, there has been a resurgence of interest in the HB alkaloids, 
with several disclosures of enantioselective syntheses within the last four years. The 
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discussion of this section will be focused on these enantioselective syntheses of the HB 
alkaloids.  
2.2.1 Schultz’s synthesis of (+)-cepharamine (2.33) 
In 1998, Schultz reported the first asymmetric synthesis of a HB alkaloid. Inspired 
by the structural resemblance to the morphinan alkaloids, Schultz prepared the unnatural 
enantiomer, (+)-cepharamine,11 featuring a highly convergent strategy dependent upon an 
asymmetric Birch reduction-alkylation protocol. To date this is the only reported 
synthesis of an unnatural HB alkaloid. 
Scheme 2.5 highlights the asymmetric Birch reduction. Benzamine 2.24, was 
prepared according to literature procedures in five steps from commercially available 2-
bromo-5-methoxybenzoic acid; Birch reduction of 2.24, with potassium in NH3 (l), 
THF/t-BuOH (1 equiv) at –78 °C, followed by addition of LiBr and the alkylation reagent 
2.25 provided 1,4-cyclohexadiene 2.26, as a single diastereomer, in 95 % yield. 
 Scheme 2.5. Asymmetric Birch reduction and alkylation of benzamide 2.24.  
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With the success of the asymmetric Birch reduction the authors set out to close 
the A–B–C ring system utilizing a radical mediated cyclization to form both the C9–C14 
and C12–C13 bonds of (+)-cepharamine (2.33) (Scheme 2.6).  
Scheme 2.6. Radical cyclization of A–B–C ring system.  
 
Enol ether hydrolysis and reduction of 2.26 with NaBH4 gave a mixture (•1:1) of 
diastereomerically related alcohols. Protection of the phenolic hydroxyl group as the 
formate ester and allylic oxidation with tert-butyl hydrogen peroxide and CuBr gave 
enone 2.27. Ketalization of 2.27 under aprotic conditions provided the radical cyclization 
precursor 2.28. The formation of the A-B-C ring system occurred upon treatment of 2.28 
with AIBN and tributyltin hydride, in refluxing toluene. Basic hydrolysis of the formate 
ester gave 2.29. 
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Completion of the synthesis commenced with the very efficient Hofmann-type 
rearrangement of 2.29 to give the cyclic carbamate 2.30 (Scheme 2.7). Formation of the 
cis-fused N-methylpyrrolidine ring was then effected in one experimental operation by 
treatment of 2.30 with lithium aluminum hydride in refluxing THF. Swern oxidation of 
2.31 provided a ketone, which was immediately converted into the enolate under O-
alkylation conditions and reacted with MeI to afford enol ether 2.32. Finally, acid-
catalyzed ketal and MOM ether hydrolysis proceeded, without disruption of the enol 
ether, to give (+)-cepharamine (2.33) in 97 % yield. 
Scheme 2.7. Completion of (+)–cepharamine 
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Although the authors mentioned the structural similarities between (–)-morphine 
(1.1) and (+)-cepharamine (2.33) and expressed interest in probing the biological activity 
of this unnatural HB alkaloid, there have been no reports of these biological studies.  
2.2.2 Reisman synthesis of (–)-8-demethoxyrunanine  
More recently, the Reisman12 group reported a unified strategy for the 
enantioselective syntheses of the HB alkaloid (–)-8-demethoxyrunanine (2.44), and the 
structurally related alkaloids, (–)-cepharatine A, C, and D. This strategy called for the 
construction of an appropriate azapropellane skeleton, followed by systematic 
introduction of the peripheral oxidations, as dictated by the target 
compound.  
The authors envisioned formation of the azapropellane skeleton 
from the intramolecular Friedel-Crafts reaction of a dihydroindolone 
substrate, such as the one depicted in Figure 2.3.  
 
Figure 2.4. Predicted electrophilic aromatic substitution in the Friedal-Crafts reaction. 
The regioselectivity of the Friedal-Crafts reaction would be controlled by the 
steric factors driving the electrophilic aromatic substitution, directing substitution to the 
less sterically encumbered para-position. The stereocenter at C14 was to be installed 
using the previously developed97 stereoselective alkylation of a mono-ketal-derived N-
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tert-butanesulfide (2.36, Scheme 2.8) with an organometallic reagent, such as Grignard 
2.37.  
The desired N-tert-butanesulfinimine, 2.36, was prepared from commercially 
available phenol 2.34 (Scheme 2.8). Phenol 2.34 was dearomatized with the hypervalent 
iodide reagent, PIDA to give an intermediate cyclohexadienone, which was trapped as the 
N-tert-butanesulfinimine, 2.36. Addition of Grignard reagent 2.37 at low temperatures 
followed by an in situ N-methylation provided sulfinamide 2.38, which was isolated as a 
single diastereomer, 96:4 dr, in 77 % yield. The authors noted that the hydrolysis of the 
dimethyl acetal occurs during the mildly acidic workup without detectable quantities of 
undesired dienone-phenol rearrangement products. 
Scheme 2.8. Synthesis of cyclohexadienone 2.38. 
 
 
 
 
 
 
The requisite pyrrolidine ring was constructed in a three-step sequence, beginning 
with a Pd-catalyzed cross coupling between vinyl bromide 2.38 and ethoxyvinylstannane 
2.49 to give enol ether 2.40 in 90 % yield (Scheme 2.9). Brief exposure of 2.40 to 1M 
HCl in THF at 0 °C resulted in cleavage of the sulfinamide and promoted intramolecular 
condensation to form an indolone. Chemoselective reduction of the indolone with sodium 
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borohydride and acetic acid furnished the desired dihydroindolone 2.41, in 96 % yield 
over two steps. 
 
Scheme 2.9. Construction of the requisite pyrrolidine ring. 
 
The authors had hoped to perform the pivotal azapropellane-forming Friedel-
Crafts reaction by treating 2.41 with a Lewis acid. Unfortunately treatment of 2.41 with 
the Lewis acid BF3•OEt2 led low to moderate yields of the desired azapropellane. 
Happily, turning to the use of a strong Brønsted acid, such as TfOH, markedly increased 
the yields to 97 % (Scheme 2.10).  
Scheme 2.10. Completion of the synthesis of (–)-(8)-demethoxyrunanine (2.44) 
 
With the azapropellane core formed, the authors installed the C7 methoxy group 
by treating 2.42 with tert-butylhydroperoxide (TBHP) and Triton B in THF to form the 
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epoxide 2.43. It was noted that epoxide 2.43, was unstable in the presence of silica gel, 
leading to rearrangement products, therefore Florisil was utilized for the purification of 
epoxide. Additionally epoxide 2.43 was found to have a strong affinity for rearranging to 
the cepharatine skeleton 2.51 (Scheme 2.11). Presumably through a nitrogen-assisted 
epoxide opening, 2.45, followed by β-elimination to give enol 2.50, which is 
subsequently trapped to form the hemiaminal 2.51 bearing the cepharatine skeleton. 
Scheme 2.11. Rearrangement of epoxide 2.43 to cepharatine skeleton 2.51 
 
 Despite issues with stability, (–)-8-demethoxyrunanine (2.44) was afforded from 
epoxide 2.43 by treatment with tetrabutylammonium methoxide. This concise synthesis 
provided access to the natural product in 9 steps from the commercially available phenol 
2.34, in a 19 % overall yield. To date this is the shortest reported synthesis of a HB 
alkaloid however, it is not without limitations.  
The formation of indolone 2.41 (Scheme 2.9) required extensive experimentation 
and all attempts at isolation of the desired des-N-methyl- indolone resulted in failure, 
increasing the difficulty for pursuing analogs bearing non-methyl N-alkyl groups. 
CHAPTER 2. THE HASUBANAN ALKALOIDS 
 
  
34
Additionally, there were significant stability issues with epoxide 2.43 during the 
installation of the C7 methoxy group (Scheme 2.11). 
2.2.3 Herzon enantioselective synthesis of (–)-hasubanonine, (–)-runanine, and (–)-
delavayine 
2.2.3.a Retrosynthetic analysis 
Coinciding with the Reisman synthesis of (–)-8-demethoxyrunanine, Herzon and 
co-workers13 disclosed a unified route to several HB alkaloids, including the parent 
compound (–)-hasubanonine (2.1), as well as, (–)-runanine (2.2), (–)-delavayine (2.3), 
and (+)-periglaucine B.  
While slightly longer, the Herzon strategy is more amenable to analog synthesis. 
This was accomplished through the development of a strategy in which the A and B rings 
of the hasubanan skeleton are formed through the reaction of a pro-nucleophile, such as 
2.53 and the azaquinone 2.52 (Scheme 2.12). The pro-nucleophile 2.53 serves as a 
branching point for incorporation of the varying arene substitution patterns found in the 
A ring of the HB alkaloids. The azaquinone 2.52 contains the trioxygenated 
cyclohexanone fragment common to the C ring of the HB alkaloids as well as the 
electrophilic sites (labeled a and b) for attachment of 2.53. 
Scheme 2.12. Herzon retrosynthetic plan for analog synthesis. 
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The authors noted that bicyclic azaquinones such as 2.52 are unstable, 
isomerizing to 5-hydroxyindole (2.54) by a proposed tautomerization and a 1,5-hydrogen 
atom shift, as shown (Scheme 2.13). The authors planned to mitigate this pathway 
through the transient introduction of a quaternary center on the azaquinone (at position 
b). The introduction of this quaternary center was to be accomplished by a Diels-Alder 
reaction of azaquinone 2.55 and 5-trimethylsilylcyclopentadiene 2.56; a Staudinger 
reaction would then afford the tetracyclic imine 2.57. Following bond formation to the 
imine (position a), the unsaturation required for addition to position b was to be 
regenerated by a retro-cycloaddition reaction, rendering 2.57 functionally equivalent to 
2.52. Additionally, it was envisioned that the cyclopentene fragment of 2.57 would 
provide a handle for stereocontrol through an enantioselective Diels-Alder reaction. 
Scheme 2.13. Proposal for mitigating rearrangement of 2.52 
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2.2.3.b Synthesis of Diels-Alder adduct 2.57 
The synthesis of the key Diels-Alder adduct 2.57 began with the preparation of 5-
(2-azidoethyl)-1,2,3-trimethoxybenzene (2.58) which was available in three steps from 
commercial reagents. Subsequent oxidation of 2.58 with hydrogen peroxide in formic 
acid afforded quinone 2.55 in a 48 % yield (Scheme 2.14). The regio- and stereoselective 
Diels–Alder reaction of 2.55 with 5-trimethylsilylcyclopentadiene (2.56) was mediated 
by the protonated form of the Corey–Bakshi–Shibata oxazaborolidine 2.59, producing the 
endo adduct in 93 % ee. Staudinger reduction of the Diels-Alder adduct provided the 
imine 2.57.  
Scheme 2.14. Synthesis of key Diels-Alder adduct 2.57. 
 
At this point, alkylation of imine 2.57 with the appropriately substituted A-ring 
appendage would provide access to several HB alkaloids as well as 
set the crucial C14 stereocenter. However, 2.57 needed to first be 
activated toward addition to the carbon–nitrogen π–bond (Figure 
2.4). This was done by treatment with methyl triflate at – 60 °C. 
Figure 2.5. Activated iminium 2.60 
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The temperature profile of this step was found to be critical; lower temperatures 
resulted in incomplete methylation, whereas further warming promoted rapid retro-
cycloaddition of the iminium salt 2.60. With the optimal activation conditions determined 
the syntheses of (–)-hasubanonine (2.1), (–)-runanine (2.2), (–)-delavayine (2.3), and (+)-
periglaucine B could be completed.  
2.2.3.c Completion of (–)-hasubanonine (2.1), (–)-runanine (2.2), and (–)-delavayine 
Scheme 2.15. Completion of the synthesis of (–)-hasubanonine (2.1) 
 
 
 
 
 
 
 
 
The completion of the synthesis of (–)-hasubanonine (2.1) (Scheme 2.15) 
commenced with the treatment of the iminium salt 2.60 with the acetylide 2.61 at – 90 
°C, resulting in the formation of the 1,2-addition product 2.62 in 62 % yield as a single 
detectable diastereomer (verified by 1H NMR analysis). The relative stereochemistry of 
the addition product 2.62 was assigned by elaboration to (–)-hasubanonine (2.1) and X-
ray crystallography of later intermediates. Retro-cycloaddition of 2.62 was achieved, in 
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an 86 % yield by heating in toluene at 135 °C. Chemoselective hydrogenation using 
Crabtree’s catalyst furnished the cis alkene 2.63. A three-step sequence comprising acid-
mediated cyclization, de-bromination, and hydrogenation provided synthetic (–)-
hasubanonine (2.1). This synthetic pathway was used to prepare both (–)-runanine (2.3) 
and (–)-delavayine with minimal modifications (Scheme 2.16) 
Scheme 2.16. Completion of (–)-runanine (2.3) and (–)-delavayine (2.4). 
 
Again, the key iminium salt 2.60 was reacted with the acetylide bearing the 
appropriate A-ring substitutions (for (–)-runanine, 2.64 and for (–)-delavayine, 2.67). 
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Retro Diels-Alder followed by reduction with Crabtree’s catalyst gave intermediates 2.56 
and 2.69. These cis alkenes were each treated with triflouroacetic acid in MeCN, 
followed by reduction to yield the natural products in 5 steps from the common 
intermediate iminium salt 2.60.  
2.2.3.d Completion of (+)- periglaucine B 
(+)-Periglaucine B bears the same A ring substitution as (–)-delavayine and 
therefore was directly accessed from the cis alkene intermediate 2.69 (Scheme 2.17) 
through a formal olefin hydration/conjugate addition sequence.  
Scheme 2.17. Completion of (+)-periglaucine B 
 
After surveying a number of conditions to effect this transformation, the authors 
found that the desired hydration product 2.70 could be formed by heating a mixture of 
2.69 and cobalt bis(acetylacetonate) in isopropanol under an atmosphere of oxygen. The 
diastereoselectivity in the hydration step was 2.2:1 in favor of 2.70. Addition of excess 
formic acid directly to the reaction mixture promoted cyclization of 2.70, providing (+)-
periglaucine B (2.71) in 55 % yield. 
  These represent the first enantioselective syntheses of (–)-hasubanonine (2.1), (–
)-runanine (2.2), (–)-delavayine (2.3), and (+)-periglaucine B (2.71). The route to each 
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target proceeds in ten to twelve steps from commercially available reagents. Like the 
Reisman synthesis this route relies on substrate control for the formation of the 
stereogenic C14 center. Additionally the N-methyl is required for activation of iminium 
2.60, limiting the type of N-substituted analogs that can be prepared. 
The authors expressed interest in studying the biological activities of these compounds 
and recently the results of cytotoxicity studies in human gastric cancer cells were 
published revealing that (–)-hasubanonine (2.1) and (–)-runanine (2.2) were sub-
micromolar inhibitors of cancer cell growth.98 However, to date no studies on the 
analgesic properties of the prepared HB alkaloids have been disclosed.  
2.3 Biological Implications of Structural Similarities**  
The resurgence in interest in the HB alkaloid is not only based the synthetic 
challenges associated with the construction of the HB skeleton, but is also due to the 
structural resemblance to the morphinan alkaloids.9 As discussed in the previous section, 
Schulz and co-workers noted that the natural configuration of the HB alkaloids is 
“enantiomeric” to morphine, and suggested that the unnatural enantiomers of the HB 
alkaloids might demonstrate analgesic activity. However, no biological activity studies of 
(+)-cepharamine have been reported, nor have any analgesic studies been conducted on 
the other more recently, prepared HB alkaloids. Furthermore only limited studies on 
isolated alkaloids have been conducted. 
                                                 
**
 This section is part of a NIH R21-R33A1 grant proposal, submitted November 2012 
CHAPTER 2. THE HASUBANAN ALKALOIDS 
 
  
41
2.3.1 Opioid receptor binding studies 
In 2010, Quinn and co-workers reported the first study examining the affinity of 
natural HB alkaloids toward the δ opioid receptor.10 Out of the limited number of 
compounds they investigated, longanine (2.5) was found to be the most potent binder to 
DOR (IC50 = 700 nM). In comparison, sinococuline 2.72, a known “enantiomeric” 
morphinan alkaloid, has an IC50 of 37 µM for the same receptor, Figure 2.5. This IC50 
value is in agreement with the previous observation that the binding affinity of (+)-
morphine is much weaker than the natural enantiomer;99–101 highlighting the specificity of 
the opioid receptors, with respect to the spatial placement of the required functional 
groups. 
 
 
 
 
 
 
Figure 2.6. Structural similarities of longanine (2.5) and known morphinan enantiomer 
sinococuline (2.72). 
2.3.2 Receptor binding analysis 
Since all of the tested compounds in Quinn’s study were isolated from natural 
sources, they are of the opposite absolute configuration and therefore conclusions cannot 
be drawn about the analgesic properties of the ent-HB alkaloids from these studies.  
Figure 2.6, illustrates support for the hypothesis that ent-HB alkaloids will bind to the 
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opioid receptors. Here we show the energy-minimized structures of (–)-morphine (1.1) 
(Figure 2.6 (a)), and ent-hasubanonine (Figure 2.6 (b)). The aromatic A ring of each 
compound is oriented down and the N-methyl group of each (pink bond) to the left. As 
can be seen the pharmacophore region of morphine (blue bonds) aligns remarkably well 
with the A, B, and D rings of ent-2.73 (blue bonds). It should also be noted that the N-
methyl groups of each compound are also in a similar spatial arrangement. 
 
 
Figure 2.7. (a) Energy-minimized structure of (–)-morphine (1.1). (b) Energy-minimized 
structure of ent-hasubanonine . 
The largest difference between the two structures in Figure 2.6 is found in the 
position of the C rings (red bonds). Upon rotating the two structures 90º so they are 
viewed down the edge of the A ring, it becomes clear that the C ring of ent-hasubanonine 
is oriented at about a 60º angle relative to the C ring of morphine. Previous studies on 
morphine derives showed that modifications to the C ring are generally well tolerated and 
rotate 90º
(a)
A
B
C
E
rotate 90º
(b)
A
B
C
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that these modifications can give rise to the receptor selectivity often observed with 
synthetic derivatives.102–105 This large change in C ring orientation observed with ent-
hasubanonine could give rise to receptor selectivity due to new interactions that are not 
possible with morphine-derived ligands.  
We are particularly interested in developing selective ligands for DOR, as 
antagonists of DOR have been indicated as promising therapies for neuropathic pain 
without the adverse side effects associated with MOR.73 With the recent disclosures of 
opioid receptor crystal structures we are now able to perform docking studies to better 
predict binding interactions that will lead to selectivity. 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Crystal structure of DOR with naltrinole bound, Adapted from PDB file 
4EJ4. 
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Figure 2.7 shows the interactions of the antagonist naltrinole (grey bounds), with 
DOR.61 The dashed yellow lines represent the approximate orientation of the HB alkaloid 
C ring, if ent-hasubanonine was bound in the DOR. The HB alkaloid C ring is positioned 
closer to TM2 and TM3, whereas, the indole ring of the bound ligand is positioned closer 
to TM6 and TM7. Sequence analysis106 of the DOR reveals K108 to be an interesting 
target for designing ligands that are selective for this receptor. This residue is an 
asparagine in MOR and a valine in KOR. Thus, it is reasonable to propose that an OR 
ligand capable of projecting an acidic functional group toward K108 would be more 
selective for binding the DOR.  
2.3.3 Closing Remarks 
Decades after their discovery, the HB alkaloids are still of interest to the synthetic 
community. While synthetically challenging, the primary reason for this interest has been 
due to the structural similarities to the morphinan alkaloids. There have been numerous 
synthetic studies on the HB alkaloids as well as recent disclosures of enantioselective 
syntheses but there have been no biological studies performed; nor have any unnatural 
analogs of the HB alkaloids been prepared and tested.  
As discussed in Chapter One, there remains a significant need for the 
identification of novel and selective opioid receptor ligands. With the crystal structures of 
each of the opioid receptors finally available, we are now poised to develop such novel 
ligands and propose that the ent-hasubanan alkaloids and their derivatives would be ideal 
candidates. The remainder of this dissertation will discuss our strategy for the synthesis 
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of HB alkaloid analogs, particularly focusing on our efforts toward the 
aza[4.4.3]propellane HB core. 
  
46
CHAPTER 3                   
PROGRESS TOWARD                               
THE HB ALKALOID CORE 
3.1 Synthetic Strategy 
3.1.1 Retrosynthetic analysis 
Our planned route (Scheme 3.1) differs from previous syntheses in that the 
formation of the C12–C13 and C14–N bonds are integrated with the formation of the B 
and D rings. This strategy is accomplished through the iodine(III) mediated oxidative 
dearomatization of an intermediate such as 3.2, which in turn, arises from a Pd catalyzed 
cross coupling of aryl-halide 3.3 and appropriate coupling partner, 3.4. Intermediate 3.2 
bears both the C ring (3.3) and A ring (3.4) moieties of the final product allowing us to 
access a majority of the HB alkaloids through this common intermediate 
Scheme 3.1. Oxidative dearomatization for the formation of the HB core. 
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As discussed in Chapter Two, structural differences between the HB alkaloid family 
members are primarily found in the oxygen substitutions of the aromatic A ring (for 
examples see Figure 2.1), while little variation occurs in the C ring. Based on this, we 
hypothesized that the same starting material, gallic acid or isovanillin, could be used for 
all of the HB analogs, whereas the A ring would come from a benzaldehyde (3.5, Scheme 
3.2) with varying substitutions.  
 Scheme 3.2. Construction of the common intermediate 3.2. 
 
 
 
 
 
 
 
3.1.2 Possible dearomatization scenarios 
The proposed dearomatization of 3.2 could lead to one of two possible scenarios 
(Scheme 3.3). The first involves initial attack by the nitrogen to give fused bicycle 3.6. 
The use of hypervalent iodide for the formation of C–N bonds has been investigated,107–
111
 however, generally these reactions lead the formation of amine spirocycles, with 
limited precedence for the formation of fused bicycles,112 in our case we believe the five 
membered fused bicycle 3.6, will be preferential to a less stable four membered amine 
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spriocycle.112 Assuming the desired bicycle is formed, addition of a Lewis acid113–115 to 
3.6 would then result in conjugate addition of the electron-rich aryl ring to provide 3.1; 
similar to the method used by Reisman, except, we anticipated being able to perform this 
sequence in a single pot without purification of the bicyclic intermediate.  
Scheme 3.3. Possible scenarios for the dearomatization of 3.2. 
 
 
 
 
 
 
 
   
In the other dearomatization scenario, the aryl ring serves as the initial 
nucleophile leading to the formation of spirocycle 3.7. Treating 3.7 with a Lewis acid 
would then promote migration of the arene together with addition of the proximal 
nitrogen. This sequence would also result in the formation of tetracycle 3.1. While similar 
migrations of arene moieties have been reported to occur in the presence of Brønsted 
acids,116–118 all have resulted in the formation of biaryl products. To the best of our 
knowledge, a nucleophile has not been used to trap the cationic intermediate generated 
during the migration. To test the feasibility of the proposed regioselective Lewis acid 
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promoted aryl migration, we investigated a simple model system (Scheme 3.4). †† 
Treating phenol 3.8 with 1 equiv. of PIDA, followed by BF3•OEt2 smoothly promoted the 
desired rearrangement. Importantly the only product observed by NMR was the one in 
which aryl ring, A, had migrated to the olefin without the methoxy group, 3.10. In this 
particular case, aromatization by proton loss was too facile to allow the intermediate 
carbocation to be trapped by a nucleophile. Fortunately, aromatization is not possible 
when the aryl group in 3.7 rearranges. 
Scheme 3.4. Regioselectivity of LA promoted aryl migration. 
 
3.2 Synthesis of dearomatization substrate 
  Confident in our synthetic strategy we set out to construct the intermediate 3.2 for 
our dearomatization studies. The biaryl 3.2 (Scheme 3.1) is composed of the A ring, 3.4, 
and C ring, 3.3 connected through an ethane bridge. Initially we proposed the use of a Pd 
catalyzed Sonogashira cross coupling reaction to connect 3.3 and 3.4. Our hope was to 
utilize the newly formed alkyne as an additional point of derivatization. The A ring 
moiety was to be accessed from a Corey-Fuchs olefination of a benzaldehyde bearing 
                                                 
††
 Dr. Rodolfo Tello-Aburto conducted this experiment. 
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appropriate substitutions, whereas the C ring was to be derived from either isovanillin or 
gallic acid. The synthetic studies began with the construction of aryl halide 3.3 from 
gallic acid. 
3.2.1 Construction of C ring moiety from gallic acid 
3.2.1.a Demethylation attempts 
Control of the regiochemistry during halogenation was to be achieved through 
selective protection of a single meta-hydroxyl group in gallic acid. The initial strategy 
employed to achieve this desymmetrization was the mono-demethylation of the 
symmetrically substituted trimethoxy-methyl gallate,119 3.12 (Scheme 3.5).  
Scheme 3.5. Selective demethylation of trimethoxy-methyl gallate 3.12. 
 
To accomplish this, gallic acid was transesterified to give methyl gallate, 3.11, which was 
further treated with an excess of potassium carbonate and dimethyl sulfate to give the 
trimethylated product, 3.12. Unfortunately, in our hands, only the para-demethylated 
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product was isolated when 3.12 was treated with sulfuric acid, and we were unable to 
afford the desired meta-demethylation, even upon switching to Lewis acids.119   
3.2.1.b Mono-benzylated substrate 
With the lack of success in the demethylation strategy, our attention turned to the 
selective protection of methyl gallate (Scheme 3.6). Formation of the orthoformate 
3.14120 allowed for mono-benzylation of the 5-hydroxyl group which was accomplished 
through deprotonation of 3.14, with potassium carbonate followed by treatment with 
benzyl bromide. Hydrolysis of the orthoformate in 3.15 gave the mono-benzylated 
methyl gallate, 3.16. Alternately, we found that methyl gallate could be desymmetrized in 
a single pot (Pathway B, Scheme 3.6) via catechol boronate121 formation followed by 
benzylation and hydrolysis (Scheme 3.6, pathway B), giving 3.16 in a 68 % yield.  
Scheme 3.6. Desymmetrization of methyl gallate. 
 
  
 
 
 
 
 
 The selective bromination of 3.16 with 1,3-dibromo-5,5-dimethylhydantoin, 
DBDMH,122 gave mono-brominated arene 3.17 in an 86 % yield (Scheme 3.7). The 
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regioselectivity of this bromination was verified by NOE correlations between the 
aromatic proton and the benzylic protons of the benzyl ether. The hydroxyl groups of 
3.17 were then dimethylated in the presence of excess potassium carbonate and dimethyl 
sulfate to give 3.18. It should be noted that 3.16 could be methylated prior to bromination, 
however it was found that the yields were substantially higher if the bromination was 
performed prior to the methylation.  
Scheme 3.7. Regioselective bromination of 3.16. 
 
 
3.2.2 Sonogashira coupling strategy 
3.2.2.a Attempted coupling of methyl benzoate derivative 
At this point, we were ready to attempt the proposed Sonogashira coupling to 
connect the A and C ring fragments. A Corey-Fuchs olefination was performed on 
CHAPTER 3. PROGRESS TOWARD THE HB CORE 
 
  
53
commercially available 4-methoxybenzaldehyde to produce the A ring containing alkyne 
3.21 (Scheme 3.8). 
Scheme 3.8. Corey-Fuchs olefination of 4-methoxybenzaldehyde. 
  
 
Aware of the potential difficulties associated with oxidative addition to electron 
rich aryl-halides,123,124 we were not surprised that our initial conditions led to 
dimerization of the alkyne (Table 3.1, entry 1).  
Table 3.1. Attempts at Sonogashira Coupling. 
 
 
Entry Catalyst Loading Solvent ∆, time 
1 2 mol % Et2NH 60 °C, 16 h 
2 2 mol % Et2NH µW, 60 °C, 10 min 
3 5 mol % Et2NH µW, 80 °C, 10 min 
4 10 mol % Et2NH µW, 80 °C, 20 min 
5 2 mol % Et3N µW, 80 °C, 10 min 
6 5 mol % Et3N µW, 100 °C 20 min 
7 10 mol % Et3N Reflux, 16 h 
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However, we were surprised to find that the desired coupling failed regardless of catalyst 
loading and the use of µW or prolonged heating.125 The starting material 3.18 and 
homodimers of alkyne where the only products isolated. 
3.2.2.b Attempted coupling of benzylic nitrile derivative 
The consistent isolation of the starting material, 3.18, confirmed our suspensions 
about the difficult nature of oxidative addition into this electron rich aromatic ring. We 
sought to perturb the electronics, and reduce some of steric bulk around the Ar–Br bond 
by converting the ester into a benzylic nitrile (Scheme 3.9). A benzylic nitrile was chosen 
as it could be readily converted into the ethanamine present in our dearomatization 
precursor 3.2.  
Scheme 3.9. Attempted Sonogashira coupling of nitrile 3.24. 
 
 
 
 
 
 
 
 
The careful reduction of aryl-bromide 3.18 afforded the benzylic alcohol, 3.22. 
Monitoring of the temperature during this reaction was crucial as increased reaction 
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temperatures led to dehalogenated products. An SN2 displacement of the intermediate 
benzylic bromide 3.23, gave nitrile 3.24, which unfortunately also proved to be 
incompatible with Sonogashira coupling.  
In additional efforts to increase the efficiency of oxidative addition we exchanged 
the Ar–Br for a more labile Ar–I bond. Originally a formal Finkelstein reaction, 
involving bromine-idodine exchange, was proposed for converting aryl bromide 3.18 to 
an aryl iodide, however, all attempts were unsuccessful in performing this transformation 
and instead, silver trifluoroacetate was employed to install the Ar–I (Scheme 3.10).  
Scheme 3.10. Preparation of aryl iodide 3.26. 
 
Benzoate 3.16 was dimethylated and treated with silver trifluoroacetate and iodine 
in chloroform at 0 °C, giving an inseparable mixture of isomers. Fortunately, introduction 
of the Ar–I on the benzylic alcohol 3.28 yielded a separable mixture, however, no 
selectivity was observed, with a 1:1 mixture of isomers isolated.  
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We sought to resolve the regioselectivity issues by employing a bulkier silyl 
group on the C3-hydroxyl (Scheme 3.11). Methyl gallate was refluxed with 
triethylorthoacetate,‡‡ and amberlyst 15E in benzene to give 3.31 in a 76 % yield. The 
free hydroxyl group of 3.31 was then protected as the TIPS ether; reduction of the 
benzoate ester with LAH, followed silver trifluoroacetate promoted iodination gave 
benzylic alcohol 3.34. Consecutive SN2 displacements on the benzylic carbon afforded 
benzylic nitrile 3.35. Disappointingly though, 3.35, was also inactive toward Pd oxidative 
addition. 
 Scheme 3.11. Preparation of aryl iodide 3.35. 
 
                                                 
‡‡
 The methyl orthoformate derivative was found to be unstable to iodination conditions 
and premature removal of the group led to substantial purification issues. 
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3.2.3 Construction of C ring moiety from isovanillin 
At this juncture, we decided to modify our synthetic plan and construct the C ring 
from isovanillin. The absence of the ortho-methoxy group was thought to alleviate the 
oxidative addition issues associated with the gallic acid substrate. Additionally, 
isovanillin was substantially easier to manipulate synthetically then gallic acid; being 
converted into the desired coupling partner in five steps (Scheme 3.12).  
Again, we aimed to control the regiochemistry of the halogenation by utilizing a 
bulky protecting group on the C5 hydroxyl. Therefore isovanillin was converted to the 
silyl ether, 3.36. Bromination was carried out by slow addition of bromine in chloroform 
to the substrate 3.36 suspended in sat’d. aq. sodium bicarbonate. It was found that any 
build up HBr caused hydrolysis of the TIPS group, which led to inseparable mixtures of 
mono- and di-brominated products. The regiochemistry of this bromination was 
confirmed by analysis of the aromatic coupling constants. Reduction of 3.37 with sodium 
borohydride gave benzylic alcohol 3.38, which was tosylated prior to µW assisted 
cyanide displacement to yield benzylic nitrile 3.39.  
Scheme 3.12. Preparation of C ring from isovanillin. 
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With 3.39 in hand, the Sonogashira reaction was attempted (Scheme 3.13). Yet 
again it failed, yielding alkyne dimers and starting aryl bromide 3.39. However, we did 
find that prolonged reaction times, at high temperatures, yielded some de-halogenated 
material, leading us to believe that oxidative addition is possible, albeit sluggish, with the 
isovanillin scaffold. Bolstered by these findings we began to explore other Pd catalyzed 
cross couplings that may prove more fruitful than the proposed Sonogashira coupling. 
Scheme 3.13. Attempted Sonogashira coupling of 3.39 and 3.21. 
 
 
 
 
 
3.2.4 Suzuki-Miyaura coupling strategy. 
3.2.4.a Aryl-Potassium trifluoroborate Suzuki coupling 
Still weary from our initial foray into Pd catalyzed reactions, we looked toward 
exploiting a Suzuki-Miyaura cross coupling to afford 3.2. Since 1998, there has been a 
myriad of studies on development of phosphine ligands and other catalyst systems for 
improving oxidative addition in Suzuki couplings.126–130 Inspired by these studies as well 
as Molander’s success with alkynyl potassium trifluoroborates,131 we believed that a 
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carefully designed Suzuki-Miyaura cross coupling could afford our desired Sonogashira 
adduct. 
To this end, alkyne 3.21 was smoothly converted to trifluoroborate 3.40 (Scheme 
3.14 (a)) in a two-step process of deprotonation and trapping with trimethyl borate 
followed by exchange with potassium bifluoride. The recrystallized trifluoroborate was 
then coupled with aryl-bromide 3.39 in the presence of Pd(OAc)2, K3PO4, and the bulky 
phosphine ligand S-Phos (Scheme 3.14 (b)). To our delight, the Suzuki coupling afforded 
a very modest yield of our desired adduct 3.41, however, further optimization efforts 
failed to increase the yields.  
Scheme 3.14. (a) Conversion of alkyne 3.21 to potassium trifluoroborate 3.40. (b) Suzuki 
coupling of 3.39 and alkynyl trifluoroborate 3.40. 
 
Continuing our misfortune, efforts to reduce the benzylic nitrile in 3.41132 to a 
primary amine were met with substantial decomposition. A cursory NMR analysis of the 
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decomposition products indicates instability in the alkyne moiety, however a thorough 
investigation of these products was not conducted.  
3.2.4.b Aryl-sp3 Suzuki coupling 
The instability of 3.41 was thought to have played a role in our futile attempts to 
optimize the yields of the coupling reaction. With this in mind we began looking into the 
coupling of a completely saturated system, such as the one depicted in Figure 3.1, where 
an aryl-sp3 bond is made and the secondary amine is already installed.  
 
 
 
 
Figure 3.1. Proposed aryl-sp3 alkyl Suzuki coupling. 
 
Aryl bromide 3.42 would again come from isovanillin. We envisioned installing 
the secondary amine through a Henry reaction followed by reduction of the nitro olefin 
and protection. From our previous work with isovanillin, it was known that the TIPS 
ether was fairly acid labile and it was presumed that a more robust protecting group 
would be needed for the preparation of 3.42. After considerable experimentation we 
determined that benzyl protection of isovanillin would provide the requisite steric bulk 
for the regioselective bromination while being robust enough to withstand acidic reaction 
conditions.  
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Deprotonation of isovanillin with potassium carbonate followed by the addition of 
benzyl bromide yielded 3.45 (Scheme 3.15). Bromination of 3.45 occurred smoothly 
giving 3.46 as a single isomer. Henry reaction of 3.46 with ammonium acetate in 
nitromethane provided nitro olefin 3.47. Considerable experimentation went into 
determining optimal nitro olefin reduction conditions. Treatment of 3.47 with LAH and 
DIBALH afforded a dehalogenated primary amine, while LiBH4 failed to completely 
reduce the nitro group. Ultimately, it was found that zinc/amalgam in acidic ethanol 
smoothly reduced the nitro olefin to the primary amine 3.48 in an 85 % yield. The 
primary amine was immediately protected as the Boc carbamate 3.49. Borane 3.43 was 
prepared from the reaction of 4-methoxystyrene with 9-BBN dimer.133  
Scheme 3.15. Preparation of aryl bromide 3.49 and borane 3.43. 
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Although the synthesis of the coupling partners was successful, the desired Suzuki 
coupling was not. Numerous iterations of reaction conditions again failed to produce the 
desired adduct, a summary of our attempts can be found in the experimental appendix. 
Including converting the borane 3.43 into a potassium trifluoroborate.134 Though unlike 
our previous endeavors we saw substantial dehalogenation of starting material, indicating 
that the oxidative addition to the benzyl protected isovanillin was more significantly more 
facile. Our focus continued on the preparation of a more stable coupling adduct with the 
oxidative addition issues apparently resolved. 
3.2.5 Heck coupling strategy 
3.2.5.a Initial attempts and optimization 
Finding the alkyne containing adduct to be unstable and inability to directly 
couple the sp3 -ethane bridged A ring to our isovanillin scaffold, led us to consider a Heck 
coupling135 between the previously prepared aryl bromide 3.46 and an appropriately 
substituted styrene (Figure 3.2) to form 3.2.  
 
 
 
 
Figure 3.2. Proposed Heck coupling of styrene and 3.46. 
A model system was developed for the screening of reaction conditions,136,137 
where aryl bromide 3.46 was dissolved in DMA followed by the addition of a palladium 
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catalyst, styrene, and base. Three different catalyst systems at various loadings were 
screened: ligand-free Pd(OAc)2, Pd(OAc)2 with a P(o-tol)3 ligand, and Pd[PEPPSI] with 
sodium formate. We also performed a simple screen of bases (Table 3.2). These studies 
identified ligand-free Pd(OAc)2 conditions that afforded the stable coupling adduct 3.51 
in an impressive, un-optimized 65 % yield. Highly encouraged by these results we set out 
to further optimize the reaction with the styrene. 
Table 3.2. Heck reaction conditions. 
 
Entry Pd catalyst Basec Ligand/additive Temp Yield 
1 Pd(OAc)2a K2CO3 none 125 °C 65 % 
2 Pd(OAc)2a K3PO4  none 125 °C 23 % 
3 Pd(OAc)2a Et3N  none 125 °C 10 % 
4 Pd(OAc)2a Et3N  P(o-tol)3 (10 mol %) 125 °C 43 % 
5 Pd[PEPPSI]b Et3N  NaCO2H (10 mol %) 125 °C 9 % 
6 Pd[PEPPSI]b Et3N  NaCO2H (10 mol %) 80 °C 0 % 
7 Pd[PEPPSI]a Et3N  NaCO2H (10 mol %) 125 °C 50 % 
a
 2 mol % catalyst loading, b 5 mol % catalyst loading, c2 equiv of base 
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The yields were increased, up to 72 % (Scheme 3.16), when the reaction solvent, 
DMA, was dried over mol sieves and rigorously degassed. Additionally it was found that 
higher temperatures (>160 °C) and µW heating led to undesirable by-products.  
Scheme 3.16. Further optimization of the Heck coupling. 
 
 
 
 
Next the optimized conditions were used with electron rich styrenes, similar to 
those found in the A ring of the natural products. The reaction proved compatible with 
3,4-dimethoxystryene (3.54) and 4-methoxysytrene, giving yields from 65 % to 98 %.   
Scheme 3.17. Optimized Heck Couplings with oxygenated styrenes. 
 
 
 
 
 
 
 
 
Emboldened by these positive results, we set out to perform the coupling on the 
elusive gallic acid derived substrate 3.18. The initial attempts of direct coupling between 
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4-methoxystyrene and the methyl benzoate substrate were unsuccessful yielding only 
dehalogenated starting material. Not easily discouraged, 3.18 was reduced with sodium 
diisobutyl-t-butoxyaluminum hydride138 to give aldehyde 3.55 in a single step. The 
aldehyde 3.55 was then subjected to the optimized coupling conditions. Initially the 
reaction was thought to be a failure with a majority of the aldehyde 3.56 remaining after 
heating at 125 °C overnight we presumed that this more hindered substrate was again 
plagued with oxidative addition issues. However, a close examination of the crude 1H 
NMR revealed that a small amount of 3.56 was produced. Increased temperatures (150 
°C) and longer reaction slightly improved the reaction. It should also be noted that our 
attempts to directly couple nitro olefin 3.47 or an unprotected phenol to 4-
methoxystyrene were unsuccessful. 
Scheme 3.18. Heck coupling of gallic acid derived substrate 3.18. 
   
Although the barriers to oxidative addition were not completely removed, this was 
the first Pd catalyzed reaction to gain access to a gallic acid derived coupling adduct. We 
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were also pleased to find that these alkene products were considerably more stable then 
their alkyne counterparts finally allowing us to access our dearomatization precursor.   
3.2.6 Completion of Dearomatization Precursor 
With the A and C rings coupled together we turned our attention to the installation 
of the ethylamine moiety. Henry reaction on the coupling adducts cleanly generated the 
nitro olefins 3.57, 3.58, and 3.59 (Scheme 3.19).  
Scheme 3.19. Nitro olefin formation. 
  
3.2.6.a Global Hydrogenation Strategy 
In our previous work, zinc amalgam in acidic ethanol afforded the reduction of 
the nitro olefin to the ethylamine, 3.48. It was anticipated that these conditions would not 
be suitable for these substrates due to the instability of the stilbene in presence of acidic 
protons.139 We had also learned from our previous studies that nitro olefins could be 
reduced under acidic Pd catalyzed hydrogenation conditions. This led to the proposal of a 
global hydrogenation strategy, where the formation of ethylamine coincides with benzyl 
ether cleavage and hydrogenation of the stilbene. We believed this reaction sequence 
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would be feasible, if the stilbene were fully hydrogenated prior to the introduction of 
acid.  
Our initial studies indicated that the stilbene was fully hydrogenated within the 
first 30 min of reaction time, regardless of solvent choice. Therefore, we devised a 
system where after 30 mins of reaction time, HCl was added to hopefully drive the 
reduction of the nitro olefin (Table 3.3). 
Table 3.3. Hydrogenation Screening. 
 
Entry Conditions Result 
1 Pd/C (10 mol %), HCl, MeOH decomp. 
2 Pd/C (10 mol %), HCl, THF decomp. 
3 Pd/C (10 mol %), 200 PSI, MeOH/THF R—NO2 
4 Pd/C (10 mol %), 700 PSI, MeOH/THF R—NO2 
5 Pd/C (20 mol %), 700 PSI, MeOH/THF R—NO2 
6 Pd/C (10 mol %), 200 PSI, Cl-+NHMe3 18 % 
 
Contrary to our hypothesis, we found the saturated biaryl product to also be acid sensitive 
leading to undetermined decomposition products (entries 1 and 2). Because of this acid 
CHAPTER 3. PROGRESS TOWARD THE HB CORE 
 
  
68
sensitivity we attempted to drive the reduction of the vinyl nitro by increasing 
hydrogenation pressures in a Parr bomb reactor.  
 Unfortunately reduction of the nitro group was not achieved without some proton 
source, even with increasing the pressures up to 700 PSI (entries 4-5). The addition of a 
weak proton source such as trimethyl ammonium chloride afforded the fully reduced 
amine and the crude NMR indicated that the conversion was clean, however there were 
significant issues with isolation of the amine product leading us to abandon this route.  
3.2.6.b Multi-step strategy 
 Instead we employed a multi-step strategy, where the nitro olefin is first reduced 
with LAH and protected, followed by hydrogenation of the double bond and benzyl ether 
(Scheme 3.20). 
Scheme 3.20. Completion of dearomatiztion precursor. 
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LAH reduction of 3.58, in refluxing THF afforded a primary amine, which was 
immediately protected as either: a tosyl-amine, 3.60, or Troc-carbamate 3.61. This 
protection was critical to the success of the subsequent hydrogenation as unprotected 
amines resulted in poor yields presumably due to catalyst poisoning. Both the Troc-
carbamate and tosylamine substrates were hydrogenated to give the biaryl coupling 
adducts 3.62 and 3.63. The Heck coupling synthetic route yields the desired 
dearomatization precursors in 7 steps from isovanillin and 10 steps from gallic acid.  
3.3 Dearomatization/Acid Catalyzed Cyclization 
3.3.1 Discussion of dearomatization strategy 
Finally achieving the synthesis of our precursor we were poised to complete the 
HB alkaloid core via a hypervalent iodine(III) mediated oxidative dearomatization. As a 
reminder, we proposed two possible scenarios for this dearomatization: (1) the nitrogen 
serves as the nucleophile, leading to a fused bicyclic intermediate, and (2) where the 
aromatic A ring serves as the nucleophile forming a spirocycle intermediate (Scheme 
3.21). Spirocyclizations such as the one proposed in our second scenario are well 
known140 however, the trapping of the rearrangement product is unprecedented. The 
formation of the fused bicycle in our first scenario is also unprecedented in the literature.  
Scheme 3.21. Possible scenarios for the dearomatization of 3.2, revisited. 
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The 
first 
example of an iodine(III) mediated C–N bond formation was reported in 2002 by 
Ciufolini and co-workers (Scheme 3.22).108 In this example, tosyl-amine 3.64 forms 
spirocycle 3.65 when treated with PIFA. Other examples of C–N bond forming reactions 
have been reported,109 but to date all involve the formation of a spirocycle. The closest 
example to our proposal was reported by Quideau and co-workers in 2001.112 Here 
phenol 3.66 is treated with PIDA to give the stable ketal intermediate 3.67, removal of 
the nitrogen protecting group with TBAF leads to bicycle formation followed by 
rearomatization to give phenol 3.68. While PIDA is used to form the ketal intermediate 
the authors observed that the C–N bond formation is ultimately a result of amine 
deprotection. 
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Scheme 3.22. Examples of hypervalent iodine(III) mediated C–N bond formation. 
 
 
 
 
 
 
 
 
Both a carbamate 3.63 and a tosyl-amine 3.62 protected substrate were prepared. 
Based on literature reports, 3.62 was expected to be compatible with scenario one. We 
hoped in lieu of formation of a hindered 4 membered spirocycle the tosyl-amine would 
attack at the para position to yield the fused bicycle.  
3.3.2 Results of dearomatization 
3.3.2.a Treatment of tosyl-amine 3.62 with hypervalent iodide(III) reagents 
The traditional hypervalent iodide (III) reagent PIDA, as well as, the more 
electrophillic µ-oxo-bridged diiodide reagent were used in the dearomatization of tosyl-
amine 3.62 (Scheme 3.23). Treatment of 3.62 with PIDA provided the stable, fused 
bicycle 3.69 confirming that addition of the nitrogen is more facile than spirocyclization 
of the arene. An identical cyclohexadienone was formed when 3.62 was treated with the 
diiodide reagent. 
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Table 3.4.Treatment of tosyl-amine 3.62 with hypervalent iodide(III) reagents. 
 
- 
 
 
 
 
 
Entry I(III) reagent Solvent Temp/Time Conversion by TLC 
1 PIDA DCM 0 °C/ 180 min 60 % 
2 Diiodide TFE –40 °C/ 90 min 100 % 
3 Diiodide TFE 0 °C/ 30 min 100 % (66 % isolated yield) 
4 Diiodide DCM 0 °C/ 30 min 100 % (70 % isolated yield) 
 
The diiodide reagent proved to be more effective at producing the 
cyclohexadieneone 3.69, showing 100 % conversion at 0 °C in 30 minutes. Hypervalent 
iodide(III) reagents like the µ-oxo-bridged diiodide possess a more ionic character than 
PIDA or PIFA. This increase in electrophilicity at the iodine atom has been shown to 
improve the rate of dearomatization though acceleration the initial ligand exchange.140 In 
addition to our reagent findings, we found that solvent effects do not appear to play an 
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important role in this transformation as the highly protic trifluoroethanol and DCM 
provide similar yields and reaction times.  
3.3.2.b Treatment of Troc-carbamate 3.63 with hypervalent iodide(III) reagents 
In stark contrast to tosyl-amine 3.62, treatment of Troc-carbamate 3.63 with 
diiodide gives the highly colored, unstable ortho-benzoquinone 3.71 (Scheme 3.24). The 
benzoquinone is thought to arise from an intermediate carbocation such as 3.70, where 
loss of the methyl is more facile than attach by the nitrogen nucleophile.  
Scheme 3.23. Treatment of Troc-carbamate 3.63 with hypervalent iodide(III) reagents. 
 
The reluctance of the carbamate to serve as a nucleophile was also observed in 
related studies, were the oxygen of the carbamate 3.72 was found to cyclize in place of 
the nitrogen to form a six membered spirocycle 3.73. Interestingly, a similar methyl ether 
cleavage occurs when the gallic acid derived tosyl-amine is treated with diiodide 
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(Scheme 3.25). Unfortunately, the formation of the benzoquinone was persistent in both 
substrates even with varying the solvent and the hypervalent iodide(III) reagent. 
Scheme 3.24. Dearomatization of gallic acid substrate 3.59. 
 
 
 
 
 
 
 
 
3.3.3 Acid catalyzed conjugate addition 
Since the dearomatization cleanly converted tosyl-amine 3.62 to the bicycle 3.69 
we were able to attempt the final acid catalyzed conjugate addition. The structure of our 
fused bicyclic 3.69 bears a striking resemblance to the dihydroindolone prepared in the 
Reisman synthesis of (–)-demethoxyrunanine (Scheme 2.10). Given these structural 
similarities we presumed that the treatment of 3.69 with excess TfOH would afford the 
acid catalyzed conjugate addition. The reaction was carried out in a single pot without 
purification of the fused bicycle, after the treatment of 3.62 with diiodide, TfOH was 
added (Scheme 3.26) and the reaction was then immediately quenched. This sequence of 
events provided interesting results. Analysis of the crude 1H NMR clearly indicated the 
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presence of a tetracyclic product, however, there appeared to be an additional product. 
This was also visible as two distinct spots on TLC.  
Scheme 3.25. Acid catalyzed conjugate addition.  
 
 
 
 
 
 
 
 
 
 
Mass spectrometry of the final product relieved the loss of a methyl group from the 
tetracycle, presumably through intermediate 3.74, leading to the formation of isomers 
3.75 and 3.76. Loss of this methyl group is extremely facile, occurring instantaneously 
upon the addition of Brønsted acid. Our current efforts are focused on screening Lewis 
acids, which will potentially mitigate the consummate demethylation of intermediate 
3.74.  
 Although the treatment of 3.62 with the µ-oxo-bridged diiodide unexpectedly 
yielded isomers 3.75 and 3.76, the tetracyclic core of the HB alkaloids was nonetheless 
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constructed in 8 steps from commercially available materials, showcasing our convergent 
dearomatization strategy. 
3.3.4 Future Work 
We are currently investigating methods for the selective methylation of 3.76. As 
well as, looking into ways to exploit the formation of the ortho-quinone 3.71. Inspired by 
Matsumoto and co-workers,141 we envision performing the dearomatization of 3.63 in the 
presence of methanol producing the simple ortho-quinone acetal 3.78 (Scheme 3.27). 
Treatment with Lewis acid would then lead to the conjugate addition of the aryl ring 
giving intermediate (3.78), followed attack of the nucleophillic nitrogen to eliminate the 
acetal, affording the tetracyclic core 3.80.  
Scheme 3.26. Trapping of the ortho-quinone 3.71.   
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3.3.5 Closing Remarks 
Many challenges were endured and overcome during the preparation of the HB 
alkaloid tetracyclic core. After extensive experimentation, we developed a unique 
synthetic route, highlighted by the integration of the formation of the C12–C13 and C14–
N bonds with the formation of the B and D rings.  
This strategy features an unprecedented iodine(III) mediated oxidative 
dearomatization for the formation of a fused nitrogen bicycle. Most importantly, the 
simplicity of this route allows for the preparation both natural and unnatural HB alkaloids 
in less than nine steps from commercially available materials, without the use of 
expensive or exotic reagents; furthering drug discovery efforts for the treatment of 
chronic pain. 
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EXPERIMENTAL APPENDIX 
 Materials and Methods 
Unless otherwise stated, reactions were performed in flame- or oven-dried 
glassware under an argon or nitrogen atmosphere using anhydrous solvents. Acetic acid 
was distilled from acetic anhydride with CrO3 or KMnO4. Acetonitrile, CH2Cl2, and 
toluene were dried by passage through an activated alumina column under nitrogen. 
Dimethyl sulfoxide (DMSO) was placed over activated alumina overnight, and then 
distilled from CaH2 and stored over 4Å molecular sieves. Methanol was dried over 3Å 
molecular sieves. 1,4-Dioxane and tetrahydrofuran (THF) were distilled from 
sodium/benzophenone. Powdered 4Å molecular sieves were activated by heating under 
vacuum and stored at 90 ºC until use. Pd(OAc)2 was purchased from Strem Chemicals. 
Unless otherwise stated, reactions were monitored using thin-layer chromatography 
(TLC) using plates precoated with silica gel XHL w/ UV254 (250 µm) and visualized by 
UV light or KMnO4, phosphomolybdic acid, or anisaldehyde stains, followed by heating. 
Silica gel (particle size 32–63 µm) was used for flash column chromatography. 1H and 
13C NMR spectra are reported relative to the residual solvent peak (δ 7.26 and δ 77.2 for 
1H and 13C in CDCl3, δ 7.16 and δ 128.0 for 1H and 13C in C6D6, respectively), or 
tetramethylsilane (δ 0.00 for 1H) when the residual solvent peak is obscured. Data for 1H 
NMR spectra are reported as follows: chemical shift (ppm) (multiplicity, coupling 
constant (Hz), integration). Multiplicity is described using the following abbreviations: s 
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= singlet, d = doublet, t = triplet, q = quartet, hept = heptet, m = multiplet, bs = broad 
singlet. IR samples were prepared on NaCl plates either neat or by evaporation from 
CHCl3 or CH2Cl2. 
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methyl 3,4,5-trihydroxybenzoate (3.11) 
Into a round-bottom flask equipped with a stir bar was placed gallic acid (5.0 g, 0.29 mol), 
sulfuric acid (10 mL) and methanol (200 mL). The flask was fitted with a reflux 
condenser and slowly warmed to reflux. After refluxing overnight, the reaction was 
cooled to room temperature and concentrated by rotary evaporation. The crude product 
was recrystallized from ethanol and water (90:10) to afford a transparent crystalline 
product (5.41 g, quant.). Identity was verified by comparison of 1H NMR spectrum with 
literature data1 
 
 
 
 
 
                                                 
1
 Alam, A.; Takaguchi, Y.; Ito, H.; Yoshida, T.; Tsuboi, S. Multi-functionalization 
of gallic acid towards improved synthesis of α- and β-DDB. Tetrahedron 2005, 61, 
1909–1918. 
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methyl 3,4,5-trimethoxybenzoate (3.12) 
Into a round-bottom flask equipped with a stir bar was placed methyl 3,4,5-
trihydroxybenzoate (3.11) (500 mg, 2.7 mmol), potassium carbonate (1.87 g, 13.57 
mmol), and DMF (20.0 mL).  The flask was stirred at room temperature for 1 hour. At 
this time, dimethylsulfate (3.0 g, 8.10 mmol) was added to the mixture. After stirring 
overnight, the mixture was then quenched with H2O (60 mL) and extracted with EtOAc 
(3 x 100 mL).  The combined organic extracts were washed with brine (100 mL), dried 
with Na2SO4, filtered, and concentrated.  The resulting oil was purified by flash 
chromatography (SiO2, 10:1 hexane:EtOAc) to afford a white solid (488.6 mg, 80 %). 
Identity was verified by comparison of 1H NMR spectrum with literature data.2 
 
 
 
                                                 
2
 Brossi, A.; Guien, H.; Rachlin, A. I.; Teitel, S. Selective Demethylation of 3,4-
Dimethoxy- Substituted Aromatic Aldehydes and Ketones. J. Org. Chem. 1967, 
32, 1269–1270. 
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methyl 4-hydroxy-3,5-dimethoxybenzoate (3.13) 
Into a round-bottom flask equipped with a stir bar was placed methyl 3,4,5-
trimethoxybenzoate (3.12) (400 mg, 1.7 mmol) and sulfuric acid (10 mL). The flask was 
fitted with a reflux condenser and slowly warmed to 80 °C. After stirring overnight, the 
mixture was then cooled to room temperature and quenched with sat’ed NaHCO3 (30 
mL) and extracted with EtOAc (3 x 100 mL). The combined organic extracts were 
washed with brine (100 mL), dried with Na2SO4, filtered, and concentrated.  The 
resulting powder was purified by flash chromatography (SiO2, 8:1 hexane:EtOAc) to 
afford an amorphous white solid ( 328.2 mg, 91 %). Identity was verified by comparison 
of 1H NMR spectrum with literature data.3 
 
 
 
                                                 
3
 Prager, R. H.; Tan, Y. T. Selective Demethylation of 3,4-Dimethoxybenzaldehyde. 
Tetrahedron Lett. 1967, 38, 3661–3664. 
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methyl-7-hydroxy-2-methoxybenzo[d][1,3]dioxole-5-carboxylate (3.14) 
Into a round-bottom flask equipped with a stir bar was placed methyl gallate (3.11) (5.0 g, 
0.3 mol), Amberlyst 15E (1.5g, 15 mg/mL), methyl orthoformate (9.54 g, 0.9 mol) and 
Benzene (150 mL). The flask was fitted with a reflux condenser and slowly warmed to 
reflux. After refluxing for 4 hours, the reaction was cooled to room temperature, filtered 
and concentrated by rotary evaporation.  The residue extracted with EtOAc (3 x 100 mL).  
The combined organic extracts were washed with brine (100 mL), dried with Na2SO4, 
filtered, and concentrated.  The resulting powder was purified by flash chromatography 
(SiO2, 6:1 hexane:EtOAc) to afford an amorphous white solid ( 5.76 g, 85 %).  
1H NMR (300 MHz, CDCl3) δ 7.45 (d, 1H, J= 1.5), 7.21 (d, 1H, J=1.5), 6.95 (s, 1H), 
3.89 (s, 3H), 3.44 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 167.4, 147.9, 139.2, 137.7, 124.9, 121.0, 114.6, 103.4, 
53.1, 50.9 
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methyl-7-(benzyloxy)-2-methoxybenzo[d][1,3]dioxole-5 –carboxylate (3.15) 
Into a round-bottom flask equipped with a stir bar was placed methyl benzoate (3.14) 
(618 mg, 2.73 mmol), potassium carbonate (755.5 mg, 5.46 mmol), and DMF (27.3 mL).  
The flask was fitted with a reflux condenser and slowly warmed to 60 °C.  At this time, 
benzyl bromide (0.65 mL, 5.46 mmol) was added and the mixture warmed to 80 °C.  
After stirring overnight, the mixture was then cooled to room temperature and quenched 
with H2O (30 mL) and extracted with EtOAc (3 x 100 mL). The combined organic 
extracts were washed with brine (100 mL), dried with Na2SO4, filtered, and concentrated.  
The resulting oil was purified by flash chromatography (SiO2, 100 % hexane until 
removal of benzyl bromide, then 6:1 hexane:EtOAc) to afford an amorphous white solid 
(845.6 mg, 98 %).  
1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 5H), 7.35 (s, 1H), 7.32 (s, 1H), 6.94 (s, 1H), 
5.22 (s, 1H), 3.88 (s, 3H), 3.40 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 147.9, 139.1, 136.8, 134.3, 129.3, 128.9, 128.3, 125.0, 
120.9, 112.6, 104.2, 72.2, 52.9, 50.8 
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methyl 3-(benzyloxy)-4,5-dihydroxybenzoate (3.16) 
Into a round-bottom flask equipped with a stir bar was placed methyl-7-(benzyloxy)-2-
methoxybenzocarboxylate (3.15) (824.6 mg, 2.60 mmol), hydrochloric acid (2.5 mL, 2N) 
and MeOH (50.0 mL). After stirring at room temperature for 2 hours, the mixture was 
quenched with sat’d NaHCO3 (50 mL) concentrated by rotary evaporation. The resulting 
residue was extracted with EtOAc (3 x 100 mL). The combined organic extracts were 
washed with brine (100 mL), dried with Na2SO4, filtered, and concentrated. The resulting 
residue was purified by flash chromatography (SiO2, 100 % 1:1 hexane:EtOAc) to afford 
an amorphous white solid (684.6 mg, 96 %).  
1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 5H), 7.26 (s, 2H), 7.32 (s, 1H), 5.79 (s, 1H), 
5.33 (s, 1H), 5.12 (s, 2H) 3.88 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 155.7, 137.6, 134.7, 129.5, 129.4, 128.9, 111.8, 109.3, 
107.6, 100.9, 72.2, 52.8 
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methyl 5-(benzyloxy)-2-bromo-3,4-dihydroxybenzoate (3.17)4 
Into a round-bottom flask equipped with a stir bar and covered with foil was placed 
methyl 3-(benzyloxy)-4,5-dihydroxybenzoate (3.16) (684.6 mg, 2.40 mmol), and 
chloroform (7.0 mL). At this time, DBDMH (356.8 mg, 1.26 mmol) was added to the 
mixture After stirring at room temperature overnight, the mixture was quenched with 
sat’d Na2SO3 (10 mL) extracted with DCM (3 x 10 mL). The combined organic extracts 
were washed with brine (10 mL), dried with Na2SO4, filtered, and concentrated. The 
resulting residue was purified by flash chromatography (SiO2, 4:1 hexane:EtOAc) to 
afford an amorphous white solid (653 mg, 75 %).  
1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 5H), 7.28 (s, 1H), 5.94 (s, 1H), 5.91 (s, 1H) 
5.14 (s, 2H), 3.88 (s, 3H) 
 
 
 
                                                 
4
 Alam, A.; Takaguchi, Y.; Ito, H.; Yoshida, T.; Tsuboi, S. Multi-functionalization of 
gallic acid towards improved synthesis of α- and β-DDB. Tetrahedron 2005, 61, 1909–
1918. 
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methyl 5-(benzyloxy)-2-bromo-3,4-dimethoxybenzoate (3.18) 
Into a round-bottom flask equipped with a stir bar was placed methyl 5-(benzyloxy)-2-
bromo-3,4-dihydroxybenzoate (3.17) (690.1 mg, 1.95 mmol), potassium carbonate 
(674.46 mg, 4.88 mmol), and DMF (10.0 mL).  The flask was stirred at room temperature 
for 1 hour. At this time, dimethylsulfate (0.388 mL, 4.095 mmol) was added and the 
mixture. After stirring overnight, the mixture was then quenched with H2O (30 mL) and 
extracted with EtOAc (3 x 100 mL).  The combined organic extracts were washed with 
brine (100 mL), dried with Na2SO4, filtered, and concentrated.  The resulting oil was 
purified by flash chromatography (SiO2, 6:1 hexane:EtOAc) to afford a white solid 
(691.3 mg, 93 %).  
1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 5H), 7.24 (s, 1H), 5.06 (s, 1H), 3.89 (s, 3H), 
3.85 (s, 6H) 
13C NMR (75 MHz, CDCl3) δ 166.0, 151.2, 146.3, 135.8, 128.4, 127.9, 127.2, 127.1, 
111.7, 109.6, 70.9, 60.9, 60.8, 52.2 
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1-(2,2-dibromovinyl)-4-methoxybenzene (3.20) 
A 1.7 M solution of PPh3 (21.6 g, 0.8 mol) in dry DCM was added dropwise to a 0.7 M 
solution of CBr4 (12.1 g, 0.36 mol) in dry DCM at 0 °C, under a nitrogen atmosphere, 
over 30 minutes. The reaction was stirred at 0 °C for 30 min to develop a red slurry, 
before adding the 4-methoxybenzaldehyde (2.23 mL, 0.18 mmol) dropwise. The reaction 
was left stirring at 0 °C for 1 h. The reaction was diluted with 100 mL of DCM, which 
was followed by addition of 50 mL of petroleum ether, used to precipitate the 
triphenylphopshine oxide. The supernatant liquid was decanted and then a further 100 
mL of DCM as well as 50 mL of petroleum ether were added to the precipitate. This 
procedure was repeated once more, before drying the combined supernatant fractions 
over Na2SO4, filtering, and concentrating them under reduced pressure. The crude 
product was then dry loaded onto a silica gel column and purified by flash 
chromatography (SiO2, 20:1 hexane:EtOAc) to afford a cream yellow solid (21.0 g, 
40 %). Identity was verified by comparison of 1H NMR spectrum with literature data.5 
 
 
                                                 
5
 Michaelides, I. N.; Darses, B.; Dixon, D. J. Acid-catalyzed Synthesis of 
Bicyclo[3.n.1]alkenediones. Org. Lett. 2011, 13, 664–667. 
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1-ethynyl-4-methoxybenzene (3.21) 
To a 0.07 M solution of the 1-(2,2-dibromovinyl)-4-methoxybenzene (3.20) (2.00 g, 6.85 
mmol) in anhydrous THF at –78 °C, under a nitrogen atmosphere, n-BuLi (2.4 equiv.) 
was added dropwise. The reaction mixture was left stirring for 1h at –78 °C before 
allowing the flask to warm to room temperature for 1 h. The reaction was then cooled 
down to 0 °C and H2O (10 mL) was added in one portion. The reaction was then allowed 
to reach room temperature over 4 h. The reaction was quenched using sat’ed NH4Cl (aq) 
and extracted with EtOAc (3 x 250 mL). The combined organic extracts were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (SiO2, 20:1 hexane:EtOAc) to afford a yellow oil 
(688.02 mg, 76 %). Identity was verified by comparison of 1H NMR spectrum with 
literature data.6 
 
 
 
 
                                                 
6
 Michaelides, I. N.; Darses, B.; Dixon, D. J. Acid-catalyzed Synthesis of 
Bicyclo[3.n.1]alkenediones. Org. Lett. 2011, 13, 664–667. 
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 (5-(benzyloxy)-2-bromo-3,4-dimethoxyphenyl)methanol (3.22) 
To a solution of methyl 5-(benzyloxy)-2-bromo-3,4-dimethoxybenzoate (3.18) (150.0 mg, 
0.39 mmol) in anhydrous THF at –78 °C, under a nitrogen atmosphere, DIBALH (117.3 
mg, 0.83 mmol) was added dropwise. The reaction mixture was left stirring for 3h at –
78 °C before allowing the flask to warm to room temperature for 1 h. The reaction was 
quenched with Rochelle’s salt (10 mL) and was stirred for 1 H. At this time, the reaction 
was filtered over celite and concentrated by rotary evaporation. The crude product was 
purified by flash chromatography (SiO2, 20:1 hexane:EtOAc) to afford a cream solid 
(115 mg, 83 %). 
1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 5H), 6.95 (s, 1H), 5.12 (s, 2H), 4.65 (s, 2H), 
3.90 (s, 6H) 
13C NMR (75 MHz, CDCl3) δ 151.8, 150.7, 142.6, 136.3, 135.1, 128.4, 127.6, 127.1, 
109.2, 108.4, 70.8, 64.7, 60.9, 60.8 
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1-(benzyloxy)-4-bromo-5-(bromomethyl)-2,3-dimethoxybenzene (3.23) 
Into a round-bottom flask equipped with a stir bar was placed (5-(benzyloxy)-2-bromo-
3,4-dimethoxyphenyl)methanol (3.22) (115 mg, 0.33 mmol), PPh3 (128.6 mg, 0.49 
mmol), and DCM (7.0 mL).  The mixture was stirred at room temperature for 30 min. At 
this time, N-bromosuccinimide (87.2 mg, 0.49 mmol) was added.  After stirring overnight, 
the reaction was quenched with sat’ed NaHCO3 (10 mL) and extracted with DCM (3 x 10 
mL). The combined organic extracts were washed with brine (100 mL), dried with 
Na2SO4, filtered, and concentrated.  The resulting oil was purified by flash 
chromatography (SiO2, 100 % 20:1 hexane:EtOAc) to afford an yellow oil (85.1 mg, 
62 %). 
1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 5H), 6.88 (s, 1H), 5.12 (s, 2H), 4.57 (s, 2H), 
3.91 (s, 6H) 
13C NMR (75 MHz, CDCl3) δ 151.7, 150.5, 146.1, 143.8, 136.0, 131.9, 128.4, 127.9, 
127.2, 111.5, 70.9, 60.9, 60.8, 33.9 
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2-(5-(benzyloxy)-2-bromo-3,4-dimethoxyphenyl)acetonitrile (3.24) 
Into a round-bottom flask equipped with a stir bar was placed 1-(benzyloxy)-4-bromo-5-
(bromomethyl)-2,3-dimethoxybenzene (3.23) (85.8 mg, 0.206 mmol), KCN (20.1 mg, 
0.31 mmol), and DMSO (2.0 mL). The mixture was stirred at 60 °C for 1 hr. At this time, 
the reaction was quenched with H2O (10 mL) and extracted with EtOAc (3 x 10 mL). The 
combined organic extracts were washed with brine (100 mL), dried with Na2SO4, filtered, 
and concentrated.  The resulting oil was purified by flash chromatography (SiO2, 100 % 
20:1 hexane:EtOAc) to afford an yellow oil (52.6 mg, 70 %). 
1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 5H), 6.95 (s, 1H), 5.12 (s, 2H), 3.91 (s, 6H), 
3.78 (s 2H) 
13C NMR (75 MHz, CDCl3) δ 151.7, 150.5, 146.1, 143.8, 136.0, 131.9, 128.4, 127.9, 
127.2, 111.5, 70.9, 60.9, 60.8, 33.9 
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silver trifluoroacetate 
A literature procedure was adapted.7 To a suspension of 1.45 g. (6.25 mol) of silver oxide 
in 200 mL of water was added trifluoroacetic acid (1.36 g, 12.5 mol). The resulting 
solution was filtered, and evaporated to dryness under rotary evaporation. The dry silver 
trifluoroacetate was purified by dissolution in diethyl ether, filtering through activated 
carbon, and concentrating. Affording a colorless crystalline salt (1.18 g, 90 %). 
 
 
methyl 3-(benzyloxy)-4,5-dimethoxybenzoate (3.25) 
Into a round-bottom flask equipped with a stir bar was placed methyl 3-(benzyloxy)-4,5-
dihydroxybenzoate (3.16) (596.7 mg, 2.17 mmol), potassium carbonate (899.7 mg, 6.51 
mmol), and DMF (10.0 mL).  The flask was stirred at room temperature for 1 hour. At 
this time, dimethylsulfate (0.451 mL, 4.77 mmol) was added and the mixture. After 
stirring overnight, the mixture was then quenched with H2O (30 mL) and extracted with 
                                                 
7
 Janssen, D. E.; Wilson, C. 4‐Iodoveratrole. Org. Synth. 1963, 4, 547–549. 
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EtOAc (3 x 100 mL).  The combined organic extracts were washed with brine (100 mL), 
dried with Na2SO4, filtered, and concentrated.  The resulting oil was purified by flash 
chromatography (SiO2, 15:1 hexane:EtOAc) to afford a white solid (609.1 mg, 93 %).  
1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 5H), 7.38 (d, 1H, J = 1.2 Hz), 5.16 (s, 2H), 
3.93 (s, 3H), 3.91 (s, 3H), 3.90 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 152.8, 142.6, 142.5, 136.4, 128.3, 127.8, 125.6, 124.8, 
108.6, 106.8, 70.9, 60.7, 56.0, 51.9 
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(3-(benzyloxy)-4,5-dimethoxyphenyl)methanol (3.28) 
To a solution of methyl 3-(benzyloxy)-4,5-dimethoxybenzoate (3.25) (803.4 mg, 2.65 
mmol) in anhydrous diethyl ether (10 mL) at 0 °C, under a nitrogen atmosphere, LAH 
(151.27 mg, 3.98 mmol) was added. The reaction mixture was left stirring for 3 h at 0 °C 
before allowing the flask to warm to room temperature for 1 h. The reaction was 
quenched with Feiser method and was stirred for 1 h. At this time, the reaction was 
filtered over celite and concentrated by rotary evaporation. The crude product was 
purified by flash chromatography (SiO2, 20:1 hexane:EtOAc) to afford a white solid 
(705.1 mg, 97 %). 
1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 5H), 6.63 (d, 1H, J = 1.2 Hz), 6.61 (d, 1H, J 
= 1.2 Hz), 5.13 (s, 2H), 4.59 (d, 2H, J = 4.2 Hz), 3.87 (s, 6H), 3.82 (brs, 1H) 
13C NMR (75 MHz, CDCl3) δ 153.3, 136.8, 136.2, 128.3, 128.2, 127.9, 127.6, 127.0, 
105.7, 103.9, 70.7, 65.2, 60.7, 55.9 
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(5-(benzyloxy)-2-iodo-3,4-dimethoxyphenyl)methanol (3.29), (3.30) 
Into a round-bottom flask equipped with a stir bar was placed (3-(benzyloxy)-4,5-
dimethoxyphenyl)methanol (3.28) (369.3 mg, 1.34 mmol), dry silver trifluoroacetate 
(356.8 mg, 1.62 mmol), and DCM (10.0 mL). Iodine (357.09 mg, 1.41 mmol) was added 
portionwise. After iodine addition, the flask was stirred at room temperature for 1 h. At 
this time the mixture was filtered over celite and concentrated. The crude residue was 
extracted with DCM (3 x 50 mL).  The combined organic extracts were washed with 
brine (50 mL), dried with Na2SO4, filtered, and concentrated.  The resulting oil was 
purified by flash chromatography (SiO2, 4:1 hexane:EtOAc) to afford a white solid (3.29, 
59 %, 3.30, 41 %). 
3.29:  1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 5H), 6.98 (s, 1H), 5.13 (s, 2H), 4.61(s, 
2H), 3.88 (s, 6H) 
13C NMR (75 MHz, CDCl3) δ 152.9, 141.7, 138.0, 137.3, 136.3, 128.4, 127.8, 127.1, 
109.5, 84.8, 70.8, 69.1, 60.9, 60.7 
3.30:  1H NMR (300 MHz, CDCl3) δ 7.61 (apt d, 2H, J = 6 Hz) 7.44-7.42 (m, 5H), 5.03 
(s, 2H), 4.64(s, 2H), 3.88 (s, 6H) 
13C NMR (75 MHz, CDCl3) δ 152.8, 143.5, 141.6, 138.1, 136.3, 129.4, 128.3, 128.1, 
127.8, 127.1, 109.4, 84.7, 70.8, 69.0, 60.7 
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methyl 2-ethoxy-7-hydroxy-2-methylbenzo[d][1,3]dioxole-5-carboxylate (3.31) 
Into a round-bottom flask equipped with a stir bar was placed methyl gallate (3.11) (1.78 
g, 0.09 mol), Amberlyst 15E (48.3 mg, 15 mg/mL), trimethyl orthoacetal (4.71 g, 0.3 
mol) and Benzene (100 mL). The flask was fitted with a reflux condenser and slowly 
warmed to reflux. After refluxing for 8 h, the reaction was cooled to room temperature, 
filtered and concentrated by rotary evaporation.  The residue extracted with EtOAc (3 x 
100 mL).  The combined organic extracts were washed with brine (100 mL), dried with 
Na2SO4, filtered, and concentrated.  The resulting powder was purified by flash 
chromatography (SiO2, 15:1 hexane:EtOAc) to afford an amorphous white solid ( 1.86 g, 
76 %).  
1H NMR (300 MHz, CDCl3) δ 7.44 (dd, 1H, J = 1.5, 1.5 Hz), 7.12 (dd, 1H, J = 1.5, 1.5 
Hz), 6.42 (s, 1H), 3.88 (s, 3H), 3.61 (q, 2H J = 7.2, 14.4 Hz), 1.83 (s, 3H), 1.18 (t, 3H, J = 
7.2 Hz) 
13C NMR (75 MHz, CDCl3) δ 167.8, 148.3, 139.0, 130.1, 124.1, 114.3, 102.9, 62.1, 59.1, 
53.1, 25.3, 15.4 
 
EXPERIMENTAL APPENDIX 
 
  
110
 
methyl-2-ethoxy-2-methyl-7-((triisopropylsilyl)oxy)benzo[d][1,3]dioxole-5 
carboxylate (3.32) 
Into a round-bottom flask equipped with a stir bar was placed methyl 2-ethoxy-7-
hydroxy-2-methylbenzo[d][1,3]dioxole-5-carboxylate (3.31) (1.84 g, 7.2 mmol), 
imidazole (1.96 g, 28.9 mmol), DMAP (44.16 mg, 0.36 mmol) and DCM (24.0 mL).  The 
mixture was stirred at room temperature for 10 min.  At this time, TIPSCl (1.86 mL, 
8.67 mmol) was added and the mixture was stirred overnight.  After stirring overnight, 
the mixture was then quenched with H2O (30 mL) and extracted with DCM (3 x 100 mL). 
The combined organic extracts were washed with brine (100 mL), dried with Na2SO4, 
filtered, and concentrated.  The resulting oil was purified by flash chromatography (SiO2, 
then 20:1 hexane:EtOAc) to afford yellow oil (2.89 g, 98 %).  
1H NMR (300 MHz, CDCl3) δ 7.20 (s, 1H), 7.14 (s 1H), 3.86 (s, 3H), 3.59 (q, 2H J = 7.2, 
12 Hz), 1.79 (s, 3H), 1.26 (t, 3H, J = 7.0 Hz), 1.20 (t, 3H, J = 7.2 Hz) 1.12 (d, 18 H, J = 
7.0 Hz) 
13C NMR (75 MHz, CDCl3) δ 166.3, 147.5, 140.4, 137.9, 128.6, 123.1, 117.3, 102.5, 
58.1, 51.9, 24.4, 17.5, 14.6, 12.5 
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(2-ethoxy-2-methyl-7-((triisopropylsilyl)oxy)benzo[d][1,3]dioxol-5-yl)-          
methanol (3.33) 
To a solution of methyl 3-(benzyloxy)-4,5-dimethoxybenzoate (3.25) (7.23 g, 17.6 mmol) 
in anhydrous diethyl ether (100 mL) at 0 °C, under a nitrogen atmosphere, LAH (1.00 g, 
26.4 mmol) was added. The reaction mixture was left stirring for 4 h at 0 °C before 
allowing the flask to warm to room temperature for 1 h. The reaction was quenched with 
Feiser method and was stirred for 1 h. At this time, the reaction was filtered over celite 
and concentrated by rotary evaporation. The crude product was purified by flash 
chromatography (SiO2, 20:1 hexane:EtOAc) to afford a white solid (1.87 g, 77 %). 
1H NMR (300 MHz, CDCl3) δ 6.49 (d, 1H, J = 1.5 Hz), 6.47  (d, 1H, J = 1.5 Hz), 4.53 (d, 
2H, J = 6 Hz), 3.61 (q, 2H J = 7.0, 14.0 Hz), 1.76 (s, 3H), 1.25 (t, 3H, J = 7.0 Hz), 1.19 (t, 
3H, J = 7.2 Hz) 1.11 (d, 18 H, J = 7.2 Hz) 
13C NMR (75 MHz, CDCl3) δ 148.7, 139.4, 136.7, 135.1, 128.8, 114.3, 101.1, 66.1, 58.7, 
25.3, 18.5, 15.6, 13.4 
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(2-ethoxy-4-iodo-2-methyl-7-((triisopropylsilyl)oxy)benzo[d][1,3]dioxol-5-
yl)methanol (3.34) 
Into a round-bottom flask equipped with a stir bar was placed (2-ethoxy-2-methyl-7-
((triisopropylsilyl)oxy)benzo[d][1,3]dioxol-5-yl)methanol (3.33) (58.2 mg, 0.15 mmol), 
dry silver trifluoroacetate (40.2 mg, 0.18 mmol), and DCM (5.0 mL). Iodine (40.5 mg, 
0.16 mmol) was added portionwise. After iodine addition, the flask was stirred at room 
temperature for 1 h. At this time the mixture was filtered over celite and concentrated. 
The crude residue was extracted with DCM (3 x 10 mL).  The combined organic extracts 
were washed with brine (50 mL), dried with Na2SO4, filtered, and concentrated.  The 
resulting oil was purified by flash chromatography (SiO2, 10:1 hexane:EtOAc) to afford a 
white solid (15.2 mg, 20 %). 
1H NMR (300 MHz, CDCl3) δ 6.27 (s, 1H), 4.51 (d, 2H, J = 6 Hz), 3.61 (q, 2H J = 7.0, 
14.0 Hz), 1.77 (s, 3H), 1.25 (t, 3H, J = 7.0 Hz), 1.22 (t, 3H, J = 7.0 Hz) 1.11 (d, 18 H, J = 
7.0 Hz) 
13C NMR (75 MHz, CDCl3) δ 148.8, 139.1, 136.7, 135.1, 128.8, 114.3, 101.1, 66.1, 58.8, 
25.2, 18.5, 15.6, 13.4 
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2-(2-ethoxy-4-iodo-2-methyl-7-((triisopropylsilyl)oxy)benzo[d][1,3]dioxol-5-
yl)acetonitrile (3.35) 
Into a round-bottom flask equipped with a stir bar was placed 2-(2-ethoxy-2-methyl-7-
((triisopropylsilyl)oxy)benzo[d][1,3]dioxol-5-yl)acetonitrile (23.7 mg, 0.06 mmol), dry 
silver trifluoroacetate (14.5 mg, 0.07 mmol), and DCM (2.0 mL). Iodine (16.8 mg, 0.07 
mmol) was added portionwise. After iodine addition, the flask was stirred at room 
temperature for 1 h. At this time the mixture was filtered over celite and concentrated. 
The crude residue was extracted with DCM (3 x 5 mL).  The combined organic extracts 
were washed with brine (50 mL), dried with Na2SO4, filtered, and concentrated.  The 
resulting oil was purified by flash chromatography (SiO2, 10:1 hexane:EtOAc) to afford a 
white solid (19.8 mg, 64 %). 
1H NMR (300 MHz, CDCl3) δ 6.15 (s, 1H), 4.33 (s, 2H), 3.88 (q, 2H J = 7.0, 12.0 Hz), 
2.05 (s, 3H), 1.21 (t, 3H, J = 7.0 Hz), 1.18 (t, 3H, J = 7.0 Hz) 1.11 (d, 18 H, J = 7.0 Hz) 
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4-methoxy-3-((triisopropylsilyl)oxy)benzaldehyde (3.36) 
Into a round-bottom flask equipped with a stir bar was placed isovanillin (2.27 g, 14.9 
mmol), imidazole (4.10 g, 60.0 mmol), DMAP (91.0 mg, 0.75 mmol) and DCM (20.0 
mL).  The mixture was stirred at room temperature for 10 min.  At this time, TIPSCl 
(3.83 mL, 17.88 mmol) was added and the mixture was stirred overnight.  After stirring 
overnight, the mixture was then quenched with H2O (30 mL) and extracted with DCM (3 
x 100 mL). The combined organic extracts were washed with brine (100 mL), dried with 
Na2SO4, filtered, and concentrated.  The resulting oil was purified by flash 
chromatography (SiO2, 20:1 hexane:EtOAc) to afford white solid (4.48 g, 98 %).  
1H NMR (300 MHz, CDCl3) δ 9.81 (s, 1H), 7.44 (dd 1H, J = 2.0, 8.0 Hz), 7.38 (d, 1H, J 
= 2.0 Hz), 6.95 (d, 1H, J = 8.0 Hz), 3.89 (s, 3H), 1.24 (t, 3H, J = 7.0 Hz), 1.10 (d, 18 H, J 
= 7.0 Hz) 
13C NMR (75 MHz, CDCl3) δ 191.6, 157.2, 146.7, 130.7, 126.8, 119.9, 111.7, 56.2, 18.5, 
13.5 
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2-bromo-4-methoxy-5-((triisopropylsilyl)oxy)benzaldehyde (3.37) 
Into a round-bottom flask equipped with a stir bar was placed 4-methoxy-3-
((triisopropylsilyl)oxy)benzaldehyde (3.36) (2.30 g, 7.46 mmol), sat’ed NaHCO3 (aq) (10 
mL) and DCM (10.0 mL). The mixture was stirred at room temperature for 10 min.  At 
this time, Br2 (0.497 mL, 9.70 mmol) in DCM (10 mL) was added dropwise to the 
mixture and was stirred overnight. After stirring overnight, the mixture was then 
quenched with 10 % aq Na2SO3 (30 mL) and extracted with DCM (3 x 100 mL). The 
combined organic extracts were washed with brine (100 mL), dried with Na2SO4, filtered, 
and concentrated.  The resulting oil was purified by flash chromatography (SiO2, 20:1 
hexane:EtOAc) to afford white solid (2.68 g, 93 %).  
1H NMR (300 MHz, CDCl3) δ 10.14 (s, 1H), 7.41 (s, 1H), 7.02 (s, 1H), 3.89 (s, 3H), 1.25 
(t, 3H, J = 7.0 Hz), 1.09 (d, 18 H, J = 7.0 Hz) 
13C NMR (75 MHz, CDCl3) δ 191.3, 157.3, 146.1, 127.2, 120.4, 120.3, 116.6, 56.6, 32.7, 
18.5, 13.4 
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(2-bromo-4-methoxy-5-((triisopropylsilyl)oxy)phenyl)methanol (3.38) 
To a solution of 2-bromo-4-methoxy-5-((triisopropylsilyl)oxy)benzaldehyde (3.37) (1.21 
g, 3.1 mmol) in methanol (20 mL) at 0 °C, under a nitrogen atmosphere, NaBH4 (141.3 
mg, 3.73 mmol) was added. The reaction mixture was left stirring for 4 h at 0 °C before 
allowing the flask to warm to room temperature for 1 h. The reaction was quenched with 
10 % aq NaHCO3 (10 mL), and was stirred for 1 h. At this time, the reaction was filtered 
over celite and concentrated by rotary evaporation. The crude product was purified by 
flash chromatography (SiO2, 4:1 hexane:EtOAc) to afford a white solid (1.10 g, 91 %). 
1H NMR (300 MHz, CDCl3) δ 6.98 (apt d, 2H, J = 2.4 Hz)), 4.61 (s, 2H), 3.79 (s, 3H), 
1.24 (t, 3H, J = 7.0 Hz), 1.09 (d, 18H, J = 7.0 Hz) 
 
 
2-bromo-4-methoxy-5-((triisopropylsilyl)oxy)benzyl 4-methylbenzenesulfonate 
To a solution of (2-bromo-4-methoxy-5-((triisopropylsilyl)oxy)phenyl)methanol (3.38) 
(1.10 g, 2.8 mmol), NEt3 (0.597 mL, 4.25 mmol), DMAP (17.2 mg, 0.14 mmol) in DCM 
(15 mL) at room temperature TsCl (647.4 mg, 3.40 mmol) was added. The reaction 
mixture was left stirring overnight. The reaction was quenched with H2O (10 mL), and 
extracted with DCM (3 x 10 mL). The combined organic extracts were washed with brine 
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(100 mL), dried with Na2SO4, filtered, and concentrated.  The resulting oil was taken on 
crude. 
 
 
2-(2-bromo-4-methoxy-5-((triisopropylsilyl)oxy)phenyl)acetonitrile (3.39) 
Into a µW vial equipped with a stir bar was placed 2-bromo-4-methoxy-5-
((triisopropylsilyl)oxy)benzyl 4-methylbenzenesulfonate (1.42 g, 2.6 mmol), and KCN 
(424.6 mg, 6.52 mmol) in ACN (10 mL). The reaction mixture was µW at 100 °C for 30 
min. At this time, the reaction transferred into a round bottom flask and concentrated by 
rotary evaporation. The residue was extracted into DCM (3 x 10 mL). The combined 
organic extracts were washed with brine (100 mL), dried with Na2SO4, filtered, and 
concentrated. The crude product was purified by flash chromatography (SiO2, 4:1 
hexane:EtOAc) to afford a yellow solid (652.6 mg, 63 %). 
1H NMR (300 MHz, CDCl3) δ 6.99 (s, 1H), 6.95 (s, 1H), 4.60 (s, 2H), 3.79 (s, 3H), 1.19 
(t, 3H, J = 7.0 Hz), 1.09 (d, 18 H, J = 7.0 Hz) 
13C NMR (75 MHz, CDCl3) δ 152.3, 145.8, 129.2, 122.9, 116.7, 115.4, 116.7, 115.4, 
56.3, 46.9, 32.7, 18.5, 13.5 
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trifluoro((4-methoxyphenyl)ethynyl)-4-borane, potassium salt (3.40) 
To a 0.5 M solution of the 1-ethynyl-4-methoxybenzene (3.21) (960.2 mg, 7.26 mmol) in 
anhydrous THF at –78 °C, under a nitrogen atmosphere, n-BuLi (2.90 mL, 1.0 equiv.) 
was added dropwise. The reaction mixture was left stirring for 1h at –78 °C. At this time, 
trimethyl borate (1.21 mL, 10.89 mmol) was added and the mixture was stirred at –78 °C 
for an additional 1 h. The reaction was then allowed to reach –20 °C and  sat’ed aq KHF2 
(12 mL) was added and the mixture was stirred for 1 h. After 1 h the reaction was 
concentrated and placed on a high vac to remove the water. The residue was taken up in 
acetone and filtered. The filtrate was washed with hot acetone and precipitated with 
diethyl ether. The white solid was filtered and washed with diethyl ether and dried (1.23 
g, 70 %). Identity was verified by comparison of 1H NMR spectrum with literature data.8  
 
 
 
 
                                                 
8
  Molander, G.; Katona, B.; Machrouhi, F. J. Org. Chem. 2002, 67, 8416–8423. 
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2-(4-methoxy-2-((4-methoxyphenyl)ethynyl)-5-((triisopropylsilyl)oxy)phenyl)aceto-
nitrile (3.41) 
Into a round-bottom flask equipped with a stir bar was placed 2-(2-bromo-4-methoxy-5-
((triisopropylsilyl)oxy)phenyl)acetonitrile (3.39) (50.0 mg, 0.125 mmol), tri-potassium 
phosphate (106.13 mg, 0.5 mmol), SPhos (10.26 mg, 0.025 mmol), trifluoro((4-
methoxyphenyl)ethynyl)-borane, potassium salt (3.40) (44.80, 0.18 mmol), Pd(OAc)2 
(2.84 mg, 0.0125 mmol) and THF (1.0 mL). The flask was fitted with a reflux condenser 
and slowly warmed to reflux. After refluxing for 4 hours, the reaction was cooled to room 
temperature, filter through silica and concentrated by rotary evaporation. The resulting oil 
was purified by flash chromatography (SiO2, 10:1 hexane:EtOAc) to afford a white solid 
(16.5 mg, 28 %). 
1H NMR (300 MHz, CDCl3) δ 7.33 (d, 2H, J = 2.0, 9.0 Hz), 7.23 (s, 1H), 6.98 (s, 1H), 
6.84 (d, 2H, J = 2.0, 9.0 Hz), 3.95 (s, 2H), 3.83 (s, 3H), 3.82 (s, 3H) 1.23 (t, 3H, J = 7.0 
Hz), 1.09 (d, 18 H, J = 7.0 Hz) 
 
 
 
(4-methoxyphenethyl) 9-borabicyclo[3.3.1]nonane (3.43) 
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To a 0.5 M solution of 9-BBN dimer  (180.0 mg, 0.74 mmol), in anhydrous THF, under a 
nitrogen atmosphere, 4-methoxystyrene (198.1 mg, 1.47 mmol) was added dropwise. The 
reaction was monitored by GC for the disappearance of 4-methoxystyrene. Once the 
starting material was consumed the product was taken on crude. 
 
  
3-(benzyloxy)-4-methoxybenzaldehyde (3.45) 
Into a round-bottom flask equipped with a stir bar was placed isovanillin (3.0 g, 19.7 
mmol), potassium carbonate (8.17 g, 59.15 mmol), and ethanol (50.0 mL).  The flask was 
fitted with a reflux condenser and slowly warmed to 60 °C.  At this time, benzyl bromide 
(2.82 mL, 23.64 mmol) was added and the mixture warmed to 75 °C.  After refluxing 
overnight, the mixture was then cooled to room temperature, filtered, and concentrated by 
rotary evaporation. The residue was extracted with EtOAc (3 x 100 mL). The combined 
organic extracts were washed with brine (100 mL), dried with Na2SO4, filtered, and 
concentrated.  The resulting oil was purified by flash chromatography (SiO2, 100 % 
hexane until removal of benzyl bromide, then 5:1 hexane:EtOAc) to afford an amorphous 
white solid (4.50 g, 94 %).  
1H NMR (500 MHz, CDCl3) δ 9.82 (s, 1H), 7.48 (apt t, 1H, J = 3.0 Hz), 7.45 (s, 1H), 
7.42-7.32 (m, 5H), 7.01 (d, 1H, J = 14.0 Hz), 5.19 (s, 2H), 3.96 (s, 3H) 
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13C NMR (75 MHz, CDCl3) δ 191.5, 149.3, 136.9, 136.6, 129.3, 128.8, 128.2, 127.6, 
111.9, 111.4, 71.5, 56.9 
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5-(benzyloxy)-2-bromo-4-methoxybenzaldehyde (3.46) 
Into a round-bottom flask equipped with a stir bar was placed 3-(benzyloxy)-4-
methoxybenzaldehyde (3.45) (15.9 g, 0.065 mol), sat’ed NaHCO3 (aq) (30.0 mL) and 
DCM (30.0 mL). The mixture was stirred at room temperature for 10 min.  At this time, 
Br2 (8.4 mL, 0.16 mol) in DCM (20 mL) was added dropwise to the mixture and was 
stirred overnight. After stirring overnight, the mixture was then quenched with 10 % aq 
Na2SO3 (30 mL) and extracted with DCM (3 x 100 mL). The combined organic extracts 
were washed with brine (100 mL), dried with Na2SO4, filtered, and concentrated.  The 
resulting solid was recrystallized from 90: 10 EtOAc:hexanes to afford clear crystalline 
solid ( 19.6 g, 93 %). 
1H NMR (500 MHz, CDCl3) δ 10.15 (s, 1H), 7.47 (s, 1H), 7.42-7.32 (m, 5H), 7.07 (s, 
1H), 5.15 (s, 2H), 3.95 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 190.6, 155.1, 147.9, 135.8, 128.7, 128.2, 127.5, 126.4, 
120.6, 115.7, 112.4, 70.9, 56.5 
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(E)-1-(benzyloxy)-4-bromo-2-methoxy-5-(2-nitrovinyl)benzene (3.47) 
Into a round-bottom flask equipped with a stir bar was placed 5-(benzyloxy)-2-bromo-4-
methoxybenzaldehyde (3.46) (280.6 mg, 0.873 mmol), nitromethane (5.0 mL) and 
ammonium acetate (336.6 mg, 4.36 mmol). The flask was fitted with a reflux condenser 
and slowly warmed to 120 °C. After stirring overnight, the reaction was concentrated by 
rotary evaporation. The residue was extracted with EtOAc (3 x 10 mL). The combined 
organic extracts were washed with brine (10 mL), dried with Na2SO4, filtered, and 
concentrated. The resulting brown solid was purified by flash chromatography (SiO2, 1:1 
hexane:EtOAc) to afford an amorphous orange solid (300.5 mg, 94 %).   
1H NMR (500 MHz, CDCl3) δ 8.35 (d, 1H, J = 14.0 Hz), 7.52 (d, 1H, J = 14.0 Hz), 7.42-
7.32 (m, 5H), 7.16 (s, 1H), 7.00 (s, 1H), 5.16 (s, 2H), 3.91 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 152.2, 149.4, 137.8, 137.1, 135.5, 128.9, 128.6, 127.5, 
122.4, 119.1, 117.9, 110.1, 71.3, 56.4 
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2-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)ethan-1-amine (3.48) 
Into a round-bottom flask equipped with a stir bar was placed Zinc (0) metal (155.4 mg, 
2.37 mmol), 5 % aq HCl (5.0 mL) and HgCl2 (15.5 mg, 0.1 equiv to Zn (0)). The mixture 
cooled to 0 °C and stirred for 30 min. At this time the 5 % aq HCl was decanted and 
replaced with ethanol (10 mL). A solution of (E)-1-(benzyloxy)-4-bromo-2-methoxy-5-
(2-nitrovinyl)benzene (3.47) ( 34.6 mg, 0.09 mmol) in ethanol (5 mL) was then added 
along with conc. HCl (2-5 drops). The reaction was stirred allowing warmed to room 
temperature overnight. After stirring overnight, the reaction was filtered over celite and 
concentrated. The yellow residue was taken on crude (25.7 mg, 85 %). 
 
 
tert-butyl (5-(benzyloxy)-2-bromo-4-methoxyphenethyl)carbamate (3.49) 
Into a round-bottom flask equipped with a stir bar was placed 2-(5-(benzyloxy)-2-bromo-
4-methoxyphenyl)ethan-1-amine (3.48) (389.0 mg, 1.51 mmol), Boc2O (362.5 mg, 1.66 
mmol) and THF (10 mL). After stirring overnight, the reaction was concentrated by 
rotary evaporation. The residue was extracted with EtOAc (3 x 10 mL). The combined 
organic extracts were washed with brine (10 mL), dried with Na2SO4, filtered, and 
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concentrated. The resulting brown solid was purified by flash chromatography (SiO2, 4:1 
hexane:EtOAc) to afford an amorphous white solid (632.5 mg, 96 %).   
1H NMR (300 MHz, CDCl3) δ 7.42-7.32 (m, 5H), 7.02 (s, 1H), 6.77 (s, 1H), 5.09 (s, 2H), 
4.20 (q, 1H, J = 3.0, 6.0 Hz), 3.85 (s, 3H), 3.34 (q, 2H, J = 7.0, 12.0 Hz), 2.81 (t, 2H, J = 
7 Hz), 1.44 (s, 9H) 
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Experimental Table 1.1. Suzuki Coupling Attempts. 
 
Entry Borane/Boratea Pd catalystb/base Ligandc 
1 
 
Pd(dppf)2Cl2 
NaOH 
P(t-Bu)3 
2 
 
Pd(dppf)2Cl2 
NaOH 
P(o-tol)3 
3 
 
Pd(OAc)2 
K3PO4 
SPhos 
4 
 
Pd(OAc)2 
K3PO4 
XPhos 
5 
 
Pd(OAc)2 
K3PO4 
DavePhos 
a
 1.1 equiv, THF/H2O (10:1), b 10 mol %, c 25 mol % 
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General Ligand-Free Heck Coupling Conditions 
 
 A literature procedure was adapted.9 Aryl bromide (110.6 mg, 0.344 mmol), K2CO3 
(95.0 mg, 0.688 mmol) and Pd(OAc)2 (3.8 mg, 0.017 mmol) were combined in a 25 mL 
rb flask. The flask was evacuated and then refilled with N2 (3×). Dimethylacetamide10 
was added followed by the styrene (67.8 mg, 0.413 mmol). The reaction mixture was 
then heated to 125 °C. After 2 h the reaction mixture was cooled to rt and quenched with 
sat. aq. NH4Cl (10 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL) and 
the combined organic layers were washed with brine, dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography (4:1 hexanes/EtOAc) to afford the coupled product in 65–98 % yield. 
 
 
                                                 
9
 Reddy, M. A.; Jain, N.; Yada, D.; Kishore, C.; Vangala, J. R.; P. Surendra, R.; Addlagatta, A.; 
Kalivendi, S. V; Sreedhar, B. Design and synthesis of resveratrol-based nitrovinylstilbenes as 
antimitotic agents. J. Med. Chem. 2011, 54, 6751–6760. 
10
 DMA was degassed prior to use via 3 cycles of freeze-pump-thawing. 
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(E)-5-(benzyloxy)-4-methoxy-2-styrylbenzaldehyde (3.51) 
Using general ligand-free Heck coupling conditions, aryl bromide (3.46) was converted 
into stilbene 3.51 in 72 % yield after flash-column chromatography (1:0→4:1 
hexanes/EtOAc). 
1H NMR (500 MHz, CDCl3) δ 10.26 (s, 1H), 7.91 (d, 1H, J = 16.0 Hz), 7.55 (d, 2H, J = 
8.0 Hz), 7.48 (d, 2H, J = 8.0 Hz), 7.43 (d, 1H, J = 16.0 Hz), 7.39 (t, 4H, J = 7.0 Hz), 7.34 
(dd, 2H, J = 7.0, 16 Hz), 7.12 (s, 1H), 6.98 (d, 1H, J =16 Hz), 5.21 (s, 2H), 4.02 (s, 3H) 
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(E)-5-(benzyloxy)-2-(3,4-dimethoxystyryl)-4-methoxybenzaldehyde (3.52) 
Using general ligand-free Heck coupling conditions, aryl bromide (3.46) was converted 
into stilbene 3.52 in 64 % yield after flash-column chromatography (1:0→4:1 
hexanes/EtOAc). 
1H NMR (500 MHz, CDCl3) δ 10.25 (s, 1H), 7.77 (d, 1H, J = 16.0 Hz), 7.47 (d, 2H, J = 
8.0 Hz), 7.40 (dd, 2H, J = 4.0, 8.0 Hz), 7.33 (d, 2H, J = 8.0 Hz), 7.09 (d, 3H, J = 8.0 Hz), 
6.92 (d, 1H, J = 16.0 Hz), 6.88 (d, 1H, J = 8.0 Hz), 5.20 (s, 2H), 4.01 (s, 3H), 3.94 (s, 3H), 
3.92 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 190.1, 154.3, 149.4, 149.2, 147.8, 136.3, 136.1, 133.1, 
129.9, 128.6, 128.1, 127.5, 126.2, 121.7, 120.2, 113.6, 111.2, 109.1, 109.0, 70.9, 56.1, 
55.9, 55.8 
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(E)-5-(benzyloxy)-4-methoxy-2-(4-methoxystyryl)benzaldehyde (3.53) 
Using general ligand-free Heck coupling conditions, aryl bromide (3.46) was converted 
into stilbene 3.53 in 98 % yield after flash-column chromatography (1:0→4:1 
hexanes/EtOAc). 
1H NMR (500 MHz, CDCl3) δ 10.25 (s, 1H), 7.70 (d, 1H, J = 16.0 Hz), 7.47 (t, 4H, J = 
8.0 Hz), 7.42 (d, 1H, J = 16.0 Hz), 7.38 (t, 2H, J = 7.0 Hz), 7.33 (d, 1H, J = 7.0 Hz), 7.09 
(s, 1H), 6.93 (s, 1H), 6.91 (d, 2H, J = 4.0 Hz), 5.20 (s, 2H), 4.01 (s, 3H), 3.94 (s, 3H), 
3.92 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 190.1, 159.7, 154.3, 147.7, 136.3, 136.2, 129.6, 128.7, 
128.6, 128.1, 128.0, 127.5, 126.2, 121.4, 114.2, 113.4, 108.9, 70.9, 56.1, 55.3 
 
 
5-(benzyloxy)-2-bromo-3,4-dimethoxybenzaldehyde (3.55) 
Into a round-bottom flask equipped with a stir bar was placed sodium tert-butoxide 
(634.6 mg, 6.6 mmol) and THF (10 mL) and the mixture was cooled to 0 °C and 
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DIBALH (1.17 mL, 6.6 mmol) was added. After stirred at 0 °C for 2 h the mixture was 
further cooled to –40 °C and a solution of methyl 5-(benzyloxy)-2-bromo-3,4-
dimethoxybenzoate (3.18) (1.66 g, 5.5 mmol) in THF (10 mL) was added. After stirring 2 
h, the reaction was quenched with 10 % aq HCl (10 mL), extracted into EtOAc (3 x 50 
mL). The combined extracts were washed with Brine (50 mL), dried with Na2SO4, 
filtered and concentrated. The resulting white solid was purified by flash chromatography 
(SiO2, 4:1 hexane:EtOAc) to afford an amorphous white solid (1.33 g, 88 %). 
1H NMR (500 MHz, CDCl3) δ 10.30 (s, 1H), 7.54 (t, 3H, J = 7.0 Hz), 7.47 (d, 2H, J = 
7.0 Hz), 7.42 (s, 1H), 5.14 (s, 2H), 4.02 (s, 3H), 4.00 (s, 3H), 3.95 (s, 3H) 
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(E)-5-(benzyloxy)-3,4-dimethoxy-2-(4-methoxystyryl)benzaldehyde (3.56) 
Using general ligand-free Heck coupling conditions, aryl bromide (3.55) was converted 
into stilbene 3.56 in 40 % yield after flash-column chromatography (1:0→4:1 
hexanes/EtOAc). 
1H NMR (500 MHz, CDCl3) δ 10.15 (s, 1H), 7.52 (d, 2H, J = 8 Hz), 7.50 (d, 2H, J = 7.0 
Hz), 7.43 (t, 3H, J = 7.0 Hz), 7.37 (s, 1H), 7.32 (d, 1H, J = 16 Hz), 6.96 (d, 2H, J = 8.0 
Hz), 6.63 (d, 1H, J = 16 Hz), 5.21 (s, 2H), 4.03 (s, 3H), 3.91 (s, 3H), 3.86 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 191.0, 159.8, 151.7, 147.5, 137.9, 136.3, 131.2, 129.9, 
129.7, 128.6, 128.2, 128.1, 127.5, 117.1, 114.2, 108.2, 70.8, 61.2, 61.1, 55.4 
 
 
1-(benzyloxy)-4-((E)-3,4-dimethoxystyryl)-2-methoxy-5-((E)-2-nitrovinyl)benzene 
(3.57) 
Into a round-bottom flask equipped with a stir bar was placed (E)-5-(benzyloxy)-2-(3,4-
dimethoxystyryl)-4-methoxybenzaldehyde (3.52) (101.5 mg, 0.25 mmol), nitromethane 
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(5.0 mL) and ammonium acetate (38.6 mg, 0.50 mmol). The flask was fitted with a reflux 
condenser and slowly warmed to 120 °C. After stirring overnight, the reaction was 
concentrated by rotary evaporation. The residue was extracted with EtOAc (3 x 10 mL). 
The combined organic extracts were washed with brine (10 mL), dried with Na2SO4, 
filtered, and concentrated. The resulting brown solid was purified by flash 
chromatography (SiO2, 1:1 hexane:EtOAc) to afford an amorphous orange solid (300.5 
mg, 94 %).   
1H NMR (500 MHz, CDCl3) δ 8.39 (d, 1H, J = 14.0 Hz), 7.46 (d, 2H, J = 7.0 Hz), 7.45 (t, 
2H, J = 7.0 Hz), 7.36 (d, 2H, J = 7.0 Hz), 7.22 (d, 1H, J = 16.0 Hz), 7.10 (d, 2H, J = 7.0 
Hz), 7.08 (s, 1H), 6.98 (s, 1H), 6.89 (d, 1H, J = 16 Hz) 6.86 (d, 1H, J = 14 Hz), 5.18 (s, 
2H), 3.99 (s, 3H), 3.95 (s, 3H), 3.91 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 153.2, 149.6, 149.1, 147.7, 136.6, 136.2, 135.9, 134.8, 
133.1, 129.8, 128.6, 128.2, 127.3, 122.3, 120.1, 120.0, 112.1, 111.1, 109.8, 109.2, 71.2, 
56.1, 56.0, 55.9 
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1-(benzyloxy)-2-methoxy-4-((E)-4-methoxystyryl)-5-((E)-2-nitrovinyl)benzene (3.58) 
Into a round-bottom flask equipped with a stir bar was placed (E)-5-(benzyloxy)-3,4-
dimethoxy-2-(4-methoxystyryl)benzaldehyde (3.56) (2.70 g, 7.20 mmol), nitromethane 
(50.0 mL) and ammonium acetate (2.59 g, 36.0 mmol). The flask was fitted with a reflux 
condenser and slowly warmed to 120 °C. After stirring overnight, the reaction was 
concentrated by rotary evaporation. The residue was extracted with EtOAc (3 x 100 mL). 
The combined organic extracts were washed with brine (100 mL), dried with Na2SO4, 
filtered, and concentrated. The resulting brown solid was purified by flash 
chromatography (SiO2, 1:1 hexane:EtOAc) to afford an amorphous orange solid (2.90 g, 
97 %).   
1H NMR (500 MHz, CDCl3) δ 8.43 (d, 1H, J = 14.0 Hz), 7.49 (apt t, 4H, J = 7.0 Hz), 
7.43 (t, 2H, J = 7.0 Hz), 7.38 (d, 2H, J = 14.0 Hz), 7.25 (d, 1H, J = 16.0 Hz), 7.11 (s, 1H), 
7.00 (s, 1H), 6.96 (d, 2H, J = 8.0 Hz), 6.90 (d, 1H, J = 16 Hz) 5.18 (s, 2H), 4.02 (s, 3H), 
3.87 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 159.9, 153.3, 147.7, 136.7, 136.2, 135.7, 134.9, 132.8, 
129.4, 128.8, 128.3, 128.1, 127.4, 122.0, 120.1, 114.3, 111.9, 109.6, 71.2, 56.1, 55.3 
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1-(benzyloxy)-2,3-dimethoxy-4-((E)-4-methoxystyryl)-5-((E)-2-nitrovinyl)benzene 
(3.59) 
Into a round-bottom flask equipped with a stir bar was placed (E)-5-(benzyloxy)-3,4-
dimethoxy-2-(4-methoxystyryl)benzaldehyde (3.56) (135.3 mg, 0.329 mmol), 
nitromethane (10.0 mL) and ammonium acetate (118.5 mg, 1.6 mmol). The flask was 
fitted with a reflux condenser and slowly warmed to 120 °C. After stirring overnight, the 
reaction was concentrated by rotary evaporation. The residue was extracted with EtOAc 
(3 x 10.0 mL). The combined organic extracts were washed with brine (10.0 mL), dried 
with Na2SO4, filtered, and concentrated. The resulting brown solid was purified by flash 
chromatography (SiO2, 1:1 hexane:EtOAc) to afford an amorphous orange solid (125.8 
mg, 86 %).   
1H NMR (500 MHz, CDCl3) δ 8.37 (d, 1H, J = 14.0 Hz), 7.52-7.48 (m, 5H), 7.46 (d, 2H, 
J = 7.0 Hz), 7.43 (s, 1H), 7.36 (d, 2H, J = 14.0 Hz), 7.18 (d, 1H, J = 16.0 Hz), 6.92 (d, 2H, 
J = 7.0 Hz), 6.90 (d, 1H, J = 16.0 Hz) 5.19 (s, 2H), 4.01 (s, 3H), 3.89 (s, 3H), 3.86 (s, 3H) 
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(E)-N-(5-(benzyloxy)-4-methoxy-2-(4-methoxystyryl)phenethyl)-4-methylbenzene-
sulfonamide (3.60) 
To a solution of 1-(benzyloxy)-2-methoxy-4-((E)-4-methoxystyryl)-5-((E)-2-
nitrovinyl)benzene (3.58) (442.5 mg, 1.06 mmol) in anhydrous THF (15.0 mL) at 0 °C, 
under a nitrogen atmosphere, LAH (200.0 mg, 5.3 mmol) was added. The reaction flask 
was fitted with a reflux condenser and the reaction was slowly warmed to reflux. After 4 
h the reaction was quenched with Feiser method and was stirred for 1 h. At this time, the 
reaction was filtered over celite and concentrated by rotary evaporation. The crude 
product was purified by flash chromatography (SiO2, 20:1 hexane:EtOAc) to afford a 
white solid which was immediately dissolved in DCM (5.0 mL). To this solution was 
added sat’d aq. Na2CO3 (2 mL) and TsCl (53.5 mg, 0.280 mmol). The reaction was 
stirred overnight at room temperature. After stirring overnight, the reaction was extracted 
into DCM (3 x 10 mL). The combined extracts were and washed with Brine (10.0 mL), 
dried with Na2SO4, filtered and concentrated. The resulting yellow solid was purified by 
flash chromatography (SiO2, 4:1 hexane:EtOAc) to afford an amorphous yellow solid 
(82.0 mg, 72.0 % over 2 steps).   
1H NMR (500 MHz, CDCl3) δ 7.64 (d, 2H, J = 8.0 Hz), 7.45 (dd, 4H, J = 4.0, 8.0 Hz), 
7.40 (t, 3H, J = 7.0 Hz), 7.36 (d, 1H, J = 7.0 Hz), 7.19 (d, 2H, J = 8.0 Hz), 7.09 (s, 1H), 
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7.06 (d, 1H, J = 16.0 Hz), 6.94 (d, 2H, J = 8.0 Hz), 6.84 (d, 1H, J = 16.0 Hz), 6.64 (s, 1H), 
5.14 (s, 2H), 4.49 (t, N–H), 3.95 (s, 3H), 3.86 (s, 3H), 3.12 (q, 2H, J = 7.0, 14.0 Hz), 2.87 
(t, 2H, J = 7.0 Hz), 2.37 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 159.3, 148.8, 147.7, 143.3, 136.9, 136.8, 130.2, 129.7, 
129.6, 128.9, 128.6, 127.8, 127.7, 127.4, 127.0, 123.1, 115.7, 114.2, 109.3, 71.1, 56.2, 
55.4, 43.9, 33.3, 21.5 
 
 
2,2,2-trichloroethyl (E)-(5-(benzyloxy)-4-methoxy-2-(4-methoxystyryl)phenethyl)-
carbamate (3.61) 
To a solution of 1-(benzyloxy)-2-methoxy-4-((E)-4-methoxystyryl)-5-((E)-2-
nitrovinyl)benzene (3.58) (626.2 mg, 1.50 mmol) in anhydrous THF (25.0 mL) at 0 °C, 
under a nitrogen atmosphere, LAH (569.3 mg, 15.0 mmol) was added. The reaction flask 
was fitted with a reflux condenser and the reaction was slowly warmed to reflux. After 4 
h the reaction was quenched with Feiser method and was stirred for 1 h. At this time, the 
reaction was filtered over celite and concentrated by rotary evaporation. The crude 
product was purified by flash chromatography (SiO2, 20:1 hexane:EtOAc) to afford a 
white solid which was immediately dissolved in DCM (15.0 mL). To this solution was 
added sat’d aq. Na2CO3 (5.0 mL) and TsCl (210.6 mg, 0.994 mmol). The reaction was 
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stirred overnight at room temperature. After stirring overnight, the reaction was extracted 
into DCM (3 x 20 mL). The combined extracts were and washed with Brine (20.0 mL), 
dried with Na2SO4, filtered and concentrated. The resulting yellow solid was purified by 
flash chromatography (SiO2, 4:1 hexane:EtOAc) to afford an amorphous yellow solid 
(312.0 mg, 55.0 % over 2 steps).   
1H NMR (500 MHz, CDCl3) δ 7.49 (d, 2H, J = 8.0 Hz), 7.47 (d, 2H, J = 7.0 Hz), 7.40 (t, 
3H, J = 7.0 Hz), 7.20 (d, 1H, J = 16.0 Hz), 7.16 (s, 1H), 6.94 (d, 2H, J = 8.0 Hz), 6.87 (d, 
1H, J = 16.0 Hz), 6.72 (s, 1H), 5.17 (s, 2H), 4.63 (s, 2H), 3.97 (s, 3H), 3.86 (s, 3H), 3.42 
(q, 2H, J = 7.0, 14.0 Hz), 2.94 (t, 2H, J = 7.0 Hz) 
13C NMR (75 MHz, CDCl3) δ 159.3, 154.5, 148.8, 147.8, 136.9, 130.4, 129.9, 128.8, 
128.7, 128.6, 128.5, 128.0, 127.9, 127.7, 127.4, 123.3, 115.9, 114.3, 114.2, 109.3, 99.4, 
95.5, 77.3, 76.3, 74.4, 71.2, 56.2, 55.3, 42.3, 33.7 
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N-(5-hydroxy-4-methoxy-2-(4-methoxyphenethyl)phenethyl)-4-methylbenzene-  
sulfonamide (3.62) 
To a solution of (E)-N-(5-(benzyloxy)-4-methoxy-2-(4-methoxystyryl)phenethyl)-4-
methylbenzene-sulfonamide (3.60) (47.0 mg, 0.08 mmol) in anhydrous THF (2.0 mL), 
10 % Pd/C (9.10 mg, 0.008 mmol) was added. The reaction flask was fitted with a 
hydrogen balloon and was stirred at room temperature 8 h. After 8 h the reaction was 
filtered over celite and concentrated by rotary evaporation. The crude product was 
purified by flash chromatography (SiO2, 25:1 hexane:EtOAc) to afford a brown solid 
(31.3 mg, 86 %) 
1H NMR (500 MHz, CDCl3) δ 7.72 (d, 2H, J = 8.0 Hz), 7.27 (d, 1H, J = 8.0 Hz), 7.06 (d, 
2H, J = 8.0 Hz), 6.85 (d, 2H, J = 8.0 Hz), 6.58 (s, 1H), 6.55(s, 1H), 4.53 (br s, N–H), 3.81 
(s, 6H), 3.10 (q, 2H, J = 7.0, 14.0 Hz), 2.73 (apt s, 4H), 2.68 (t, 2H, J = 7.0 Hz), 2.42 (s, 
3H) 
13C NMR (75 MHz, CDCl3) δ 157.9, 145.2, 143.7, 143.4, 136.8, 133.5, 131.6, 129.7, 
129.4, 127.9, 127.0, 115.2, 113.8, 112.3, 55.9, 55.3, 43.9, 37.1, 34.1, 31.9, 21.5 
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2,2,2-trichloroethyl-(5-hydroxy-4-methoxy-2-(4-methoxyphenethyl)phenethyl)-
carbamate (3.63) 
To a solution of 2,2,2-trichloroethyl (E)-(5-(benzyloxy)-4-methoxy-2-(4-
methoxystyryl)phenethyl)-carbamate (3.61) (288.8 mg, 0.511 mmol) in anhydrous THF 
(10.0 mL), 10 % Pd/C (54.2 mg, 0.051 mmol) was added. The reaction flask was fitted 
with a hydrogen balloon and was stirred at room temperature 5 h. After 5 h the reaction 
was filtered over celite and concentrated by rotary evaporation. The crude product was 
purified by flash chromatography (SiO2, 15:1 hexane:EtOAc) to afford a white solid 
(105.1 mg, 43 %) 
1H NMR (500 MHz, CDCl3) δ 7.10 (d, 2H, J = 8.0 Hz), 6.86 (d, 2H, J = 8.0 Hz), 6.73 (s, 
1H), 6.61 (s, 1H), 5.56 (br s, N–H), 4.74 (s, 2H), 3.83 (s, 3H), 3.82 (s, 3H), 3.41 (q, 2H, J 
= 7.0, 14.0 Hz), 2.83 (dd, 4H, J = 7.0 Hz), 2.76 (t, 2H, J = 7.0 Hz) 
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6-methoxy-7a-(4-methoxyphenethyl)-1-tosyl-1,2,3,7a-tetrahydro-5H-                   
indol-5-one (3.69) 
To a solution of N-(5-hydroxy-4-methoxy-2-(4-methoxyphenethyl)phenethyl)-4-
methylbenzene-  sulfonamide (3.62) (22.7 mg, 0.05 mmol) in DCM (1.0 mL), µ-oxo-
bridged iodide (17.3 mg, 0.03 mmol) was added. The reaction was stirred for 30 min 
before being concentrated by rotary evaporation. The crude product was purified by flash 
chromatography (SiO2, 5:1 hexane:EtOAc) to afford a white solid (15.9 mg, 70 %) 
1H NMR (500 MHz, CDCl3) δ 7.65 (d, 2H, J = 7.0 Hz), 7.26 (d, 1H, J = 7.0 Hz), 7.03 (d, 
2H, J = 8.0 Hz), 6.83 (d, 2H, J = 8.0 Hz), 6.51 (s, 1H), 6.09 (s, 1H), 3.90 (td, 1H, J = 3.0, 
7.0 Hz), 3.80 (s, 3H), 3.66 (s, 3H), 3.62 (t, 1H, J =7.0 Hz), 2.95 (m, 1H), 2.63 (m, 1H) 
2.56 (m, 1H), 2.46 (m, 2H), 2.41 (s, 3H), 2.37 (m, 1H) 
13C NMR (75 MHz, CDCl3) δ 180.1, 161.8, 158.0, 151.4, 143.8, 137.2, 132.3, 129.6, 
129.1, 126.9, 122.7, 113.9, 112.4, 67.8, 55.3, 47.5, 42.6, 29.4, 28.3, 21.5 
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2,2,2-trichloroethyl-(2-(6-(4-methoxyphenethyl)-3,4-dioxocyclohexa-1,5- 
dien-1-yl)ethyl-carbamate (3.71) 
To a solution of 2,2,2-trichloroethyl-(5-hydroxy-4-methoxy-2-(4-
methoxyphenethyl)phenethyl)-carbamate (3.63) (60.0 mg, 0.13 mmol) in TFE (2.0 mL), 
µ-oxo-bridged iodide (40.9 mg, 0.062 mmol) was added. The reaction was stirred for 30 
min before being concentrated by rotary evaporation. The crude product was bright 
orange and was analyzed immediately without purification. 
1H NMR (500 MHz, CDCl3) δ 7.14 (d, 2H, J = 8.0 Hz), 6.88 (d, 2H, J = 8.0 Hz), 6.24 (s, 
1H), 6.22 (s, 1H), 5.33 (apt t, N–H), 4.73 (s, 2H), 3.81 (s, 3H), 3.50 (q, 2H, J = 7.0, 14.0 
Hz), 2.86 (t, 2H, J =7.0 Hz), 2.74 (t, 2H, J =7.0 Hz), 2.67 (t, 2H, J =7.0 Hz)  
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7-hydroxy-3-methoxy-11-tosyl-9,10-dihydro-8a,4b-(epiminoethano)phenanthren-
6(5H)-one (3.75 & 3.76) 
To a solution of 6-methoxy-7a-(4-methoxyphenethyl)-1-tosyl-1,2,3,7a-tetrahydro-5H-
indol-5-one (3.69)  (11.0 mg, 0.02 mmol) in DCM (0.10 mL), cooled to 0 °C, TfOH (2.1 
mg, 0.02 mmol) was added. The reaction was stirred for 1 min before being concentrated 
by rotary evaporation. The crude product was purified by flash chromatography (SiO2, 
5:1 hexane:EtOAc) to afford a white solid ( 3.8 mg, 36 %) 
1H NMR (500 MHz, CDCl3) δ 7.84 (dd, 2H, J = 2.0, 8.0 Hz), 7.36 (ddd, 2H, J = 2.0, 8.0, 
8.0 Hz), 6.75 (dd, 3H, J = 2.0, 8.0 Hz), 6.72 (d, 1H, J = 8.0 Hz), 3.79 (apt d, 1H, J = 4.0, 
6.0 Hz), 3.23 (d, 1H, J = 16.0 Hz), 2.79 (d, 1H, J = 16.0 Hz), 2.43 (apt d, 1H, J = 4.0, 6.0 
Hz), 2.30 (t, 2H, J = 7.0 Hz), 2.20 (m, 1H) 2.07 (dd, 1H, J = 6.0 Hz), 2.00 (m, 1H), 1.52 
(m, 1H), 1.40 (dd, 1H J = 6.0 Hz) 1.27 (s, 1H) 
HRMS (ESI+) m/z calcd for C24H25NO5SNa [M + Na]+ 462.1351, found 462.133 
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